<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1405233639
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Inment
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AL RAZI PHARMA INDUSTRIES FACTORY LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES FACTORY LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2312]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Inment contains the active substance escitalopram. Inment belongs to a group of antidepressants called selective serotonin reuptake inhibitors (SSRIs). These medicines act on the serotonin-system in the brain by increasing the serotonin level. Disturbances in the serotonin-system are considered an important factor in the development of depression and related diseases.<br />Inment is used to treat depression (major depressive episodes) and anxiety disorders (such as panic disorder with or without agoraphobia, social anxiety disorder, generalised anxiety disorder and obsessive-compulsive disorder).<br />It may take a couple of weeks before you start to feel better. Continue to take Inment, even if it takes some time before you feel any improvement in your condition.<br />You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-indent:50px"><strong>Do not take Inment</strong>.<br />&bull; if you are allergic to escitalopram or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you take other medicines that belongs to a group called MAO inhibitors, including selegiline (used in the treatment of Parkinson&rsquo;s disease), moclobemide (used in the treatment of depression) and linezolid (an antibiotic).<br />&bull; at the same time as taking pimozide.<br /><strong>Warnings and precautions</strong><br /><strong>Talk to your doctor or pharmacist before taking Inment. Please tell your doctor if you have any other condition or illness, as your doctor may need to take this into consideration. In particular, tell your doctor:</strong><br />If you have epilepsy. Treatment with Inment should be stopped if seizures occur for the first time, or if there is an increase in the seizure frequency (see also section 4 &ldquo;Possible side effects&rdquo;).<br />&bull; If you suffer from impaired liver or kidney function. Your doctor may need to adjust your dosage.<br />&bull; If you have diabetes. Treatment with Inment may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.<br />&bull; If you have a decreased level of sodium in the blood.<br />&bull; If you have a tendency to easily develop bleedings or bruises.<br />&bull; If you are receiving electroconvulsive treatment.<br />&bull; If you have coronary heart disease.<br />&bull; If you suffer or have suffered from heart problems or have recently had a heart attack.<br />&bull; If you have a low resting heart-rate and/or you know that you may have salt depletion as a result of prolonged severe diarrhea and vomiting (being sick) or usage of diuretics (water tablets).<br />&bull; If you experience a fast or irregular heart beat, fainting, collapse or dizziness on standing up, which may indicate abnormal functioning of the heart rate.<br />&bull; If you have or have previously had eye problems, such as certain kinds of glaucoma (increased pressure in the eye).<br /><strong>Please note</strong><br />Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.<br />Symptoms such as restlessness or difficulty in sitting or standing still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder</strong><br />If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p><strong>You may be more likely to think like this:</strong><br />a. If you have previously had thoughts about killing or harming yourself.<br />b. If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behavior in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behavior.</p><p><strong>Children and adolescents under 18 years of age</strong><br />Inment should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects such as suicide attempts, suicidal thoughts and hostility (predominately aggression, oppositional behavior and anger) when they take this class of medicines. Despite this, your doctor may prescribe Inment for patients under 18 because he/she decides that this is in their best interest. If your doctor has prescribed Inment for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any symptoms listed above develop or worsen when patients under 18 are taking Inment. Also, the long-term safety effects of Inment, concerning growth, maturation, cognitive and behavioral development in this group, have not yet been demonstrated.</p><p><strong>Inment and other medicines</strong><br /><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Tell your doctor if you are taking any of the following medicines:</strong><br />&bull; &ldquo;Non-selective monoamine oxidase inhibitors (MAOIs)&rdquo;, containing phenelzine, iproniazid, isocarboxazid, nialamide, and tranylcypromine as active ingredients. If you have taken any of these medicines, you will need to wait 14 days before you start taking Inment. After stopping Inment you must allow 7 days before taking any of these medicines.<br />&bull; &ldquo;Reversible, selective MAO-A inhibitors&rdquo;, containing moclobemide (used to treat depression).<br />&bull; &ldquo;Irreversible MAO-B inhibitors&rdquo;, containing selegiline (used to treat Parkinson&rsquo;s disease). These increase the risk of side effects.<br />&bull;The antibiotic linezolid.<br />&bull;Lithium (used in the treatment of manic-depressive disorder) and tryptophan.<br />&bull;Imipramine and desipramine (both used to treat depression).<br />&bull;Sumatriptan and similar medicines (used to treat migraine) and tramadol (used against severe pain). These increase the risk of side effects.<br />&bull;Cimetidine, lansoprazole and omeprazole (used to treat stomach ulcers), fluvoxamine (antidepressant) and ticlopidine (used to reduce the risk of stroke). These may cause increased blood levels of escitalopram.<br />&bull;St. John&#39;s wort (hypericum perforatum) - a herbal remedy used for depression.<br />&bull;Acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs (medicines used for pain relief or to thin the blood, so called anti-coagulant). These may increase bleeding-tendency.<br />&bull;Warfarin, dipyridamole, and phenprocoumon (medicines used to thin the blood, so called anti-coagulant). Your doctor will probably check the coagulation time of your blood when starting and discontinuing Inment in order to verify that your dose of anti-coagulant is still adequate.<br />&bull;Mefloquine (used to treat Malaria), bupropion (used to treat depression) and tramadol (used to treat severe pain) due to a possible risk of a lowered threshold for seizures.<br />&bull;Neuroleptics (medicines to treat schizophrenia, psychosis) and antidepressants (tricyclic antidepressants and SSRIs) due to a possible risk of a lowered threshold for seizures.<br />&bull;Flecainide, propafenone, and metoprolol (used in cardiovascular diseases) clomipramine, and nortriptyline (antidepressants) and risperidone, thioridazine, and haloperidol (antipsychotics). The dosage of Inment may need to be adjusted.<br />&bull;Medicines that decrease blood levels of potassium or magnesium, as these conditions increase the risk of life-threatening heart rhythm disorders.</p><p><br />Do not take Inment if you take medicines for heart rhythm problems or medicines that may affect the heart&rsquo;s rhythm, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (e.g. astemizole, mizolastine). If you have any further questions about this you should speak to your doctor.</p><p><strong>Inment with food, drink and alcohol</strong><br />Inment can be taken with or without food (see section 3 &ldquo;How to take Inment&rdquo;).<br />As with many medicines, combining Inment with alcohol is not advisable, although Inment is not expected to interact&nbsp;with alcohol.</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br />Inform your doctor if you are pregnant or planning to become pregnant. Do not take Inment if you are pregnant or breast-feeding, unless you and your doctor have discussed the risks and benefits involved.<br />If you take Inment during the last 3 months of your pregnancy you should be aware that the following effects may be seen in your newborn baby: trouble with breathing, bluish skin, fits, body temperature changes, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness and sleeping difficulties. If your newborn baby has any of these symptoms, please contact your doctor immediately.<br />Make sure your midwife and/or doctor know you are on Inment. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Inment may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.<br />If used during pregnancy Inment should never be stopped abruptly.<br />It is expected that Inment will be excreted into breast milk.<br />Citalopram, a medicine like escitalopram, has been shown to reduce the quality of sperm in animal studies.</p><p>Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p><strong>Driving and using machines</strong><br />You are advised not to drive a car or operate machinery until you know how Inment affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Adults</strong><br />Depression<br />The normally recommended dose of Inment is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.<br />Panic disorder<br />The starting dose of Inment is 5 mg as one daily dose for the first week before increasing the dose to 10 mg per day. The dose may be further increased by your doctor to a maximum of 20 mg per day.<br />Social anxiety disorder<br />The normally recommended dose of Inment is 10 mg taken as one daily dose. Your doctor can either decrease your dose to 5 mg per day or increase the dose to a maximum of 20 mg per day, depending on how you respond to the medicine.<br />Generalised anxiety disorder<br />The normally recommended dose of Inment is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.<br />Obsessive-compulsive disorder<br />The normally recommended dose of Inment is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.</p><p><strong>Elderly patients (above 65 years of age)</strong><br />The recommended starting dose of Inment is 5 mg taken as one daily dose. The dose may be increased by your doctor to 10 mg per day.</p><p><strong>Children and adolescents (below 18 years of age)</strong><br />Inment should not normally be given to children and adolescents. For further information please see section 2 &ldquo;What you need to know before you take Inment&rdquo;.<br />You can take Inment with or without food. Swallow the tablet with some water. Do not chew them, as the taste is bitter.<br />If necessary, you can divide the tablets by firstly placing the tablet on a flat surface with the score facing upwards. The tablets may then be broken by pressing down on each end of the tablet, using both forefingers as shown in the drawing.</p><p style="text-align:center"><img alt="" width="389" height="185" src="data:image/png;base64,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" /></p><p><strong>Duration of treatment</strong><br />It may take a couple of weeks before you start to feel better. Continue to take Inment even if it takes some time before you feel any improvement in your condition.<br />Do not change the dose of your medicine without talking to your doctor first.<br />Continue to take Inment for as long as your doctor recommends. If you stop your treatment too soon, your symptoms may return. It is recommended that treatment should be continued for at least 6 months after you feel well again.</p><p><strong>If you take more Inment than you should</strong><br />If you take more than the prescribed dose of Inment, contact your doctor or nearest hospital emergency department immediately. Do this even if there are no signs of discomfort. Some of the signs of an overdose could be dizziness, tremor, agitation, convulsion, coma, nausea, vomiting, change in heart rhythm, decreased blood pressure and change in body fluid/salt balance. Take the Inment box/container with you when you go to the doctor or hospital.</p><p><strong>If you forget to take Inment</strong><br />Do not take a double dose to make up for forgotten doses. If you do forget to take a dose, and you remember before you go to bed, take it straight away. Carry on as usual the next day. If you only remember during the night, or the next day, leave out the missed dose and carry on as usual.</p><p><strong>If you stop taking Inment</strong><br />Do not stop taking Inment until your doctor tells you to do so. When you have completed your course of treatment, it is generally advised that the dose of Inment is gradually reduced over a number of weeks.<br />When you stop taking Inment, especially if it is abruptly, you may feel discontinuation symptoms. These are common when treatment with Inment is stopped. The risk is higher, when Inment has been used for a long time or in high doses or when the dose is reduced too quickly. Most people find that the symptoms are mild and go away on their own within two weeks. However, in some patients they may be severe in intensity or they may be prolonged (2-3 months or more). If you get severe discontinuation symptoms when you stop taking Inment, please contact your doctor. He or she may ask you to start taking your tablets again and come off them more slowly.<br />Discontinuation symptoms include: Feeling dizzy (unsteady or off-balance), feelings like pins and needles, burning sensations and (less commonly) electric shock sensations, including in the head, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling anxious, headaches, feeling sick (nausea), sweating (including night sweats), feeling restless or agitated, tremor (shakiness), feeling confused or disorientated, feeling emotional or irritable, diarrhea (loose stools), visual disturbances, fluttering or pounding heartbeat (palpitations).<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The side effects usually disappear after a few weeks of treatment. Please be aware that many of the effects may also be symptoms of your illness and therefore will improve when you start to get better.<br />If you experience any of the following symptoms you should contact your doctor or go to the hospital straight away:</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>Unusual bleeds, including gastrointestinal bleeds</li></ul><p><strong>Rare (may affect up to 1 in 1000 people):</strong></p><ul><li>&nbsp;Swelling of skin, tongue, lips, or face, or have difficulties breathing or swallowing (allergic reaction).</li><li>&nbsp;High fever, agitation, confusion, trembling and abrupt contractions of muscles these may be signs of a rare condition called serotonin syndrome.</li></ul><p><strong>&nbsp;Not known (frequency cannot be estimated from the available data):</strong></p><ul><li>&nbsp;Difficulties urinating.</li><li>&nbsp;Seizures (fits), see also section 2 &ldquo;Warnings and precautions&rdquo;.</li><li>&nbsp;Yellowing of the skin and the white in the eyes are signs of liver function impairment/hepatitis.</li><li>&nbsp;Fast, irregular heartbeats, fainting which could be symptoms of a life-threatening condition known as torsade de pointes.</li><li>&nbsp;Thoughts of harming or killing yourself, see also section 2 &quot;Warnings and precautions&quot;.</li></ul><p><strong>In addition to the above the following side effects have been reported:<br />Very common (may affect more than 1 in 10 people):</strong></p><ul><li>&nbsp;Feeling sick (nausea)</li><li>&nbsp;Headache</li></ul><p><strong>Common (may affect up to 1 in 10 people):</strong></p><ul><li>Blocked or runny nose (sinusitis).</li><li>Decreased or increased appetite.</li><li>Anxiety, restlessness, abnormal deams, difficulties falling&nbsp;asleep, feeling sleepy, dizziness, yawning, tremors, prickling of the skin.</li><li>Diarrhea, constipation, vomiting, dry mouth.</li><li>Increased sweating.</li><li>Pain in muscle and joints (arthralgia and myalgia).</li><li>Sexual disturbances (delayed ejaculation, proplems with erection, decreased sexual drive and women may experience difficulties achieving orgasm).</li><li>Fatigue, fever.</li><li>Increased weight.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>&nbsp;Nettle rash (urticaria), rash, itching (pruritus).</li><li>Grinding one&rsquo;s teeth, agitation, nervousness, panic attack, confusion.</li><li>Disturbed sleep, taste disturbance, fainting (syncope).</li><li>Enlarged pupils (mydriasis), visual disturbance, ringing in the ears (tinnitus).</li><li>Loss of hair.</li><li>Excessive menstrual bleeding.</li><li>&nbsp;Irregular menstrual period.</li><li>&nbsp;Decreased weight.</li><li>&nbsp;Fast heart beats.</li><li>&nbsp;Swelling of the arms or legs.</li><li>&nbsp;Nosebleeds.</li></ul><p><strong>Rare (may affect up to 1 in 1000 people):</strong></p><ul><li>&nbsp;Aggression depersonalisation, hallucination.</li><li>&nbsp;Slow heart beats.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><ul><li>&nbsp;Decreased levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles; or confused).</li><li>&nbsp;Dizziness when you stand up due to low blood pressure (orthostatic hypotension).</li><li>&nbsp;Abnormal liver function test (increased amounts of liver enzymes in the blood).</li><li>&nbsp;Movement disorders (involuntary movements of the muscles).</li><li>&nbsp;Painful erections (priapism).</li><li>&nbsp;Signs of increased bleeding e.g. from skin and mucous membranes (ecchymosis).</li><li>&nbsp;Sudden swelling of skin or mucosa (angioedema&rsquo;s).</li><li>&nbsp;Increase in the amount of urine excreted (inappropriate ADH secretion).</li><li>&nbsp;Flow of milk in men and in women that are not nursing.</li><li>&nbsp;Mania.</li><li>&nbsp;An increased risk of bone fractures has been observed in patients taking this type of medicine.</li><li>&nbsp;Alteration of the heart rhythm (called &ldquo;prolongation of QT interval&rdquo;, seen on ECG, measuring electrical activity of the heart).</li></ul><p><strong>In addition, a number of side effects are known to occur with drugs that work in a similar way to escitalopram (the active ingredient of Inment). These are:</strong></p><ul><li>Motor restlessness (akathisia)</li><li>Loss of appetite</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use Inment after the expiry date, which is stated on the carton after EXP.<br />The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Store in the original package in order to protect from light.<br />Do not throw away any medicine via wastewater or household waste.<br />Ask your pharmacist how to throw away any medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is escitalopram.<br />Each Inment 10 mg Film-coated Tablet contains 10 mg escitalopram (as oxalate).<br />Each Inment 20 mg Film-coated Tablet contains 20 mg escitalopram (as oxalate).<br />The other ingredients are:<br />Core: Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, purified talc Magnesium stearate.<br />Coating: Hypromellose, Titanium dioxide and Polyethylene glycol / Macrogol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Inment is presented as 10 and 20 mg Film-coated Tablets.
The Film-coated Tablets are described below.
Inment 10 mg Film-coated Tablets: Oval, white, scored, film-coated tablet marked with "RZ”, “04" on each side of the score on one side of the tablet and plain on other side.
Inment 20 mg Film-coated Tablets: Oval, white, scored, film-coated tablet marked with "RZ”, “05" on each side of the score on one side of the tablet and plain on other side.
Inment 10 mg and 20 mg Film-coated Tablets are available in the following pack sizes:
28 Film-coated Tablets (2 blisters of 14’s).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alrazi Pharmaceutical Industries Factory Co., 2nd industrial city &ndash; street no. 67 cross 110<br />Building no. 3992 Dammam, Kingdom of Saudi Arabia.<br />Tel: +966 13 8281919<br />Fax: +966 13 8281313<br />Website: www.alrazi-pharma.com<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last revised in Nov. 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إنمينت على إسيتالوبرام كمادة فعالة. ينتمي إنمينت إلى مجموعة من مضادات الاكتئاب تسمى مثبطات استرداد أو استرجاع السيروتونين الانتقائية. هذه الأدوية تعمل على نظام السيروتونين في الدماغ عن طريق زيادة مستوى السيروتونين. تعتبر الاضطرابات في نظام السيروتونين عاملا مهما في تطور الاكتئاب والأمراض ذات الصلة . يحتوي إنمينت على إسيتالوبرام، ويستخدم لعالج الاكتئاب (نوبات الاكتئاب الكبرى) واضطرابات القلق (مثل اضطراب الهلع مع أو بدون الخوف من الأماكن المكشوفة، واضطراب القلق الاجتماعي، واضطراب القلق العام واضطراب الوسواس القهري).</p><p>قد يستغرق بضعة أسابيع قبل أن تبدأ في الشعور بتحسن. استمر في تناول إنمينت ، حتى لو استغرق ذلك بعض الوقت قبل أن تشعر بأي تحسن في حالتك. يجب عليك التحدث الى الطبيب إذا كنت لا تشعر بتحسن أو إذا كنت تشعر أن حالتك قد ساءت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول إنمينت </strong></p><p>&bull; اذا كانت لديك حساسية من مادة اسيتالوبرام أو أي من المكونات الأخرى للاسيتالوبرام (راجع الجزء رقم ٦).</p><p>&bull; إذا اخذت أي أدوية اخرى تنتمى لمجموعة الأدوية التي تسمى بمثبطات أم أيه أو بالإضافة إلى مستحضر سيليجينين (يستخدم لعلاج مرض الباركنسون) وموكلوبيمايد (يستخدم لعالج الاكتئاب) ولينزوليد (مضاد حيوي).&nbsp;في نفس الوقت مع مستحضر بيموزايد.</p><p><strong>التحذيرات والاحتياطات</strong></p><p><strong>تحدث مع طبيبك أو الصيدلي قبل تناول إنمينت. يرجى إخبار الطبيب إذا كان لديك أي شرط أو مرض آخر، و قد يحتاج الطبيب إلى أخذ هذا بعين الاعتبار. </strong></p><p><strong>على وجه الخصوص، أخبر طبيبك:</strong></p><p>&bull; إذا كان لديك مرض الصرع. يجب إيقاف العلاج مع إنمينت في حالة حدوث نوبات في نفس الوقت، أو إذا كان هناك زيادة في وتيرة النوبات (انظر أيضا فقرة ٤ الأعراض الجانبية المحتملة&quot;).</p><p>&bull; إذا كنت تعاني من خلل في&nbsp;وظائف الكبد أو الكلى. قد يحتاج طبيبك إلى تعديل الجرعة.</p><p>&bull; إذا كان لديك مرض السكري. قد يغير العلاج مع إنمينت السيطرة على السكر. قد تحتاج جرعة الأنسولين و / أو أدوية نقص سكر الدم عن طريق الفم إلى تعديل.</p><p>&bull; إذا كان لديك انخفاض فى مستوى الصوديوم في الدم.</p><p>&bull; إذا كان لديك ميل لحدوث النزيف أو الكدمات بسهولة، أو إذا كنت حامل (انظر &quot;الحمل، الرضاعة الطبيعية والخصوبة&quot;).</p><p>&bull; إذا كنت تتلقى العلاج بالصدمات الكهربائية.</p><p>&bull; إذا كان لديك مرض فى شريان القلب التاجي.</p><p>&bull; إذا كنت تعاني أو عانيت من مشاكل في القلب أو مررت مؤخرا بأزمة قلبية.</p><p>&bull; إذا كان لديك معدل ضربات القلب منخفض و / أو إذا حدث لك نضوب الملح نتيجة الإسهال الحاد والقيء لفترات طويلة (أن تكون مريضا) أو استخدام مدرات البول (أقراص الماء).</p><p>&bull; إذا كنت تعاني من سرعة أو عدم انتظام ضربات القلب، والاغماء، وانهيار أو الدوخة عند الوقوف، مما قد يشير إلى عمل غير طبيعي في معدل ضربات القلب.</p><p>&bull; إذا كان لديك أو عانيت في السابق من مشاكل في العين، مثل أنواع معينة من الجلوكوما (ارتفاع الضغط في العين).</p><p><strong>يرجى الملاحظة </strong></p><p>قد يدخل بعض المرضى الذين يعانون من مرض الهوس الاكتئابي في مرحلة الهوس.</p><p>يتميز هذا بالأفكار الغير عادية وسرعة التغير، والسعادة غير اللائقة والنشاط البدني المفرط. إذا واجهت هذه، اتصل بطبيبك. قد تحدث أعراض مثل الأرق أو صعوبة في الجلوس أو الوقوف أيضا خلال الأسابيع الأولى من العلاج. أخبر طبيبك فورا إذا واجهت هذه الأعراض.</p><p>التفكير في الانتحار وتفاقم الاكتئاب أو اضطرابات القلق إذا كنت مكتئبا و / أو كان لديك اضطرابات القلق يمكن أن يحدث في بعض الأحيان أفكار إيذاء أو قتل نفسك. يمكن أن تزداد عند بداية العلاج لأول مرة بمضادات الاكتئاب، لأن هذه الأدوية قد تستغرق وقتا طويلا للعمل، وعادة حوالي أسبوعين لكن في بعض الأحيان قد تحتاج لفترة أطول.</p><p>قد تكون أكثر عرضة لهذا التفكير:</p><p>&bull; إذا كان لديك تاريخ من الأفكار حول قتل أو إيذاء نفسك.</p><p>&bull; إذا كنت من الشباب البالغين. وقد أظهرت المعلومات المستقاة من التجارب السريرية زيادة خطر السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن ٢٥ عاما الذين يعانون من حالات نفسية والذين عولجوا بمضاد الاكتئاب. إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور. قد تجد أنه من المفيد إخبار قريب أو صديق حميم أنك مكتئبا أو لديك اضطراب القلق، وتطلب منهم أن يقرأ هذه النشرة. قد تسألهم اذا كانوا يعتقدون أن الاكتئاب أو القلق يزداد سوءا، أو إذا كانوا قلقين بشأن التغيرات في سلوكك.</p><p>الاستخدام لدى الأطفال والمراهقين</p><p>لا ينبغي استخدام إنمينت للأطفال والمراهقين دون سن ١٨ عاما. أيضا، يجب أن نعرف أن المرضى الذين تقل أعمارهم عن ١٨ عرضة لخطر متزايد من الأعراض الجانبية مثل محاولات الانتحار، والأفكار الانتحارية والعداء (العدوان الغالب، وسلوك المعارضة والغضب) عندما تتناول هذه الفئة من الأدوية. على الرغم من هذا، فإن طبيبك قد يصف إنمينت للمرضى دون سن ١٨ عاما لأنه / أنها قررت أن هذا فيه مصلحتهم. إذا وصف طبيبك إنمينت للمريض تحت ١٨ سنة، وترغب في مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه حدثت أو ازدادت سوءا عند المرضى الذين تقل أعمارهم عن ١٨ سنة عندما يتناولون إنمينت. أيضا، لم يتم حتى الآن اثبات آثار السلامة على المدى الطويل لاسيتالوبرام بشأن النمو والنضج والتطور المعرفي والسلوكي في هذه الفئة العمرية.</p><p>إنمينت و الأدوية الأخرى</p><p>أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو اخذت مؤخرا أي أدوية أخرى.</p><p>أخبر طبيبك إذا كنت تأخذ أي من الأدوية التالية:</p><p>&bull; &quot;مثبطات أحادي&nbsp;أمين الأوكسيديز (MAOIs&quot;)، التي تحتوي على فينيلزين، إيبرونيازيد، إيزوكربوكسازيد، نيالاميد،</p><p>وترانيلسيبرومين كمواد فعالة. إذا كنت قد اخذت أي من هذه الأدوية سوف تحتاج إلى الانتظار ١٤ يوما قبل البدء بتناول إنمينت .</p><p>بعد التوقف عن استخدام إنمينت يجب الإنتظار ٧ أيام قبل اخذ أي من هذه الأدوية:</p><p>&bull; &quot; مثبطات عكسية، انتقائية لـ A-MAO&quot; ، التي تحتوي على موكلوبميد (التي تستخدم لعلاج الاكتئاب).</p><p>&bull; &quot;مثبطات B-MAO غير عكسي&quot;، تحتوي على سيليجيلين (التي تستخدم لعلاج مرض الشلل الرعاش). قد تزيد من خطر الأعراض الجانبية.</p><p>&bull; لينزوليد المضاد الحيوي</p><p>&bull; ليثيوم (المستخدم في علاج اضطراب الهوس الاكتئابي)، والتربتوفان.</p><p>&bull; إميبرامين وديسيبرامين (كلاهما يستخدم لعلاج الاكتئاب)</p><p>&bull; سوماتريبتان والأدوية المماثلة (التي تستخدم لعلاج الصداع النصفي) وترامادول (يستخدم لعلاج الآلام الحادة). هذه تزيد من خطر الأعراض الجانبية.</p><p>&bull; سيميتيدين، النزوبرازول وأوميبرازول (التي تستخدم لعلاج قرحة المعدة)، فلوفوكسامين (اكتئاب) وتيكلوبيدين (التي تستخدم للحد من خطر السكتة الدماغية). قد تسبب هذه زيادة مستويات الدم من إسيتالوبرام.</p><p>&bull; نبتة سانت جون (هيب ركم بيرفوراتوم) - علاج بالاعشاب يستخدم لعلاج الاكتئاب.</p><p>&bull; حمض أسيتيل (سالسيليك الاسبرين) والعقاقير المضادة الالتهاب (غير الستيرويدية الأدوية المستخدمة لتخفيف الألم أو تزيد سيولة الدم، ما يسمى مضادات تجلط الدم). قد تزيد من الميل للنزيف.</p><p>&bull; وارفارين، ديبيريدامول، وفينوبروكومون (الأدوية المستخدمة لزيادة سيولة الدم ، ما يسمى مضادات تجلط الدم). من المحتمل أن يتحقق الطبيب من وقت تخثر الدم عند البدء والتوقف عن تناول إنمينت من أجل التحقق من أن جرعة مضاد تجلط الدم كافية.</p><p>&bull; ميفلوكين (التي تستخدم لعلاج الملاريا(، بوبروبيون ) التي تستخدم لعلاج الاكتئاب( وترامادول )التي تستخدم لعلاج الألم الشديد) وذلك بسبب احتمال وجود خطر خفض حد النوبات.</p><p>&bull; نيورولوبتك (الأدوية لعلاج الفصام والذهان) ومضادات الاكتئاب (مضادات الاكتئاب ثلاثية الحلقات ومثبطات استرداد أو استرجاع السيروتونين الانتقائية)نظرا لحتمال وجود خطر خفض حد النوبات.</p><p>&bull; فليكاينايد، بروبافينون، وميتوبرولول (التي تستخدم في أمراض القلب والأوعية الدموية) كلوميبرامين، ونورتريبتيلين (مضادات الاكتئاب ) وريسبيريدون، ثيوريدازين، وهالوبيريدول (مضاد الذهان). قد تحتاج الى تعديل جرعة إنمينت .</p><p>&bull; الأدوية التي تقلل مستويات البوتاسيوم أو المغنيسيوم فى الدم ، حيث تزيد هذه الظروف من خطر اضطرابات ضربات القلب التى تهدد الحياة.</p><p>لا تأخذ إنمينت إذا كنت تأخذ أدوية للمشاكل فى ضربات القلب أو الأدوية التي يمكن ان تؤثر على ضربات القلب، مثل مضادات عدم انتظام ضربات القلب من فئة IA وIII ، مضادات الذهان (مثل مشتقات الفينوثيازين، بيموزيد، هالوبيريدول)، مضادات الاكتئاب ثلاثية الحلقات، وبعض العوامل المضادة للجراثيم (على سبيل المثال سبارفلوكساسين، موكسيفلوكساسين، الاريثروميسين IV، بنتاميدين، المضادة للملاريا العلاج لا سيما هالوفانترين)، مضادات الهيستامين (على سبيل المثال استيميزول، ميزولاستين). إذا كان لديك أي أسئلة أخرى حول هذا يجب عليك التحدث مع طبيبك.</p><p>تناول إنمينت مع الطعام والشراب والكحول</p><p>يمكن تناول إنمينت مع أو بدون الطعام (انظر الفقرة ٣&quot; كيفية تناول أقراص إنمينت &quot;). كما هو الحال مع العديد من الأدوية، ليس من المستحسن الجمع بين إنمينت مع الكحول ، على الرغم من أنه ليس من المتوقع تفاعل إنمينت مع الكحول.</p><p>الحمل، الرضاعة الطبيعية والخصوبة</p><p>إذا كنت حاملا&nbsp;أو مرضعة، تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل إذا كنتِ تتناولين هذا الدواء.</p><p>لا تتناولي إنمينت إذا كنت حاملا&nbsp;أو مرضعة، إلا إذا ناقشت أنت وطبيبك المخاطر والفوائد المعنية. إذا تناولتي إنمينت خلال آخر ٣ أشهر من الحمل يجب أن تعلمي بأن التأثيرات التالية يمكن أن تحدث للمولود الجديد: مشاكل مع التنفس، و ازرقاق الجلد، تشنجات، تغييرات فى درجة حرارة الجسم، وصعوبات في التغذية، والتقيؤ، وانخفاض نسبة السكر في الدم، تصلب العضلات أو المرنة، وردود فعل قوية، ورعاش، والعصبيه، والتهيج، والخمول، والبكاء المستمر، والنعاس وصعوبات النوم. إذا حدث لطفلك حديث الولادة أي من هذه الأعراض، يرجى الاتصال بالطبيب على الفور. تأكدى أن تعلم قابلتك و / أو الطبيب انك تتناولين إنمينت . عندما يؤخذ خلال فترة الحمل، وخصوصا في آخر ٣ أشهر من الحمل، تزيد بعض الأدوية مثل إنمينت من خطر حدوث حالة خطيرة في الأطفال، تدعى ارتفاع ضغط الدم الرئوي المستمر لحديثي الوالدة (PPHN)، مما يجعل الطفل يتنفس بشكل أسرع ويظهر مزرق. عادة ما تبدأ هذه الأعراض خلال ال ٢٤ ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك يجب عليكي الاتصال بقابلتك و / أو بالطبيب على الفور. إذا استخدمت أثناء الحمل إنمينت لا ينبغي أبدا أن توقف فجأة. ومن المتوقع أن يفرز إنمينت في حليب الأم.</p><p>ثبت أن دواء سيتالوبرام، وهو دواء مثل إسيتالوبرام، أنه يحد من نوعية الحيوانات المنوية في الدراسات الحيوانية. من الناحية النظرية، وهذا قد يؤثر على الخصوبة، ولكن لم يلاحظ تأثير على الخصوبة البشرية حتى الآن.</p><p>القيادة واستخدام الآلات</p><p>ينصح بعدم قيادة السيارة أو تشغيل الآلات حتى تعرف كيف يؤثر إنمينت عليك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما هذا الدواء تماما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p>البالغين</p><p>الاكتئاب</p><p>الجرعة الموصى بها عادة من إنمينت هي ١٠ ملجم تؤخذ بجرعة واحدة يوميا. ويمكن زيادة الجرعة من قبل الطبيب بحد أقصى ٢٠ ملجم يوميا.</p><p>اضطراب الهلع</p><p>الجرعة المبدئية من إنمينت هي ٥ ملجم كجرعة واحدة يوميا في الأسبوع الأول قبل زيادة الجرعة إلى ١٠ ملجم يوميا. ويمكن زيادة الجرعة كذلك من قبل الطبيب بحد أقصى ٢٠ ملجم يوميا.</p><p>اضطراب القلق الاجتماعي الجرعة الموصى بها عادة من إنمينت هي ١٠ ملجم تؤخذ بجرعة واحدة يوميا. يمكن أن ينقص طبيبك الجرعة إلى ٥ ملجم يوميا أو زيادة الجرعة بحد أقصى ٢٠ ملجم في اليوم الواحد، وهذا يتوقف على كيفية الاستجابة للدواء.</p><p>اضطراب القلق العام الجرعة الموصى بها عادة من إنمينت هي ١٠ ملجم تؤخذ بجرعة واحدة يوميا. ويمكن زيادة الجرعة من قبل الطبيب بحد أقصى ٢٠ ملجم يوميا.</p><p>الوسواس القهري</p><p>الجرعة الموصى بها عادة من إنمينت هي ١٠ ملجم تؤخذ بجرعة واحدة يوميا. ويمكن زيادة الجرعة من قبل الطبيب بحد أقصى ٢٠ ملجم يوميا.</p><p>المرضى كبار السن(فوق ٦٥ سنة من العمر)</p><p>الجرعة الموصى بها من إنمينت هي ٥ ملجم تؤخذ بجرعة واحدة يوميا. ويمكن زيادة الجرعة من قبل الطبيب إلى ١٠ ملجم يوميا.</p><p>الأطفال والمراهقين (أقل من ١٨ سنة من العمر)</p><p>لا ينبغي عادة أن يعطى إنمينت للأطفال والمراهقين. لمزيد من المعلومات يرجى الاطلاع على قسم ٢ &quot;-مالذي تريد أن تعرفه قبل استخدامك إنمينت&quot;. يمكنك أخذ إنمينت&nbsp;مع أو بدون الطعام. إبلع القرص مع بعض الماء.لا تمضغها لأن مذاقها مر. إذا كان ولابد فإنه يمكنك تقسيم&nbsp;الأقراص بوضعها على سطح مستو وواجهة القرص إلى الأعلى ثم تكسر الأقراص بواسطة الضغط عليها على الطرفين، مستخدما الإصبعين كما هو موضح في الرسم :</p><p><img alt="" width="389" height="185" src="data:image/png;base64,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" /></p><p>مدة العلاج</p><p>قد يستغرق بضعة أسابيع قبل أن تبدأ في الشعور بتحسن. استمر في تناول إنمينت حتى لو استغرق ذلك بعض الوقت قبل أن تشعر بأي تحسن في حالتك. لا تغير جرعة الدواء دون التحدث مع طبيبك أولاً. استمر في تناول إنمينت لطالما يوصي الطبيب. إذا توقفت عن العلاج بشكل مبكر جدا، قد ترجع الأعراض الخاصة بك. فمن المستحسن أن يستمر العلاج لمدة ٦ أشهر على الأقل بعد أن تشعر بصحة جيدة ثانية.</p><p>ذا كنت تتناول إنمينت أكثر مما يجب</p><p>إذا كنت تتناول أكثر من الجرعة الموصوفة من إنمينت ، اتصل بطبيبك أو أقرب قسم الطوارئ في المستشفى على الفور. قم بذلك حتى لو لم تكن هناك علامات الانزعاج. بعض من علامات الجرعة الزائدة يمكن أن تكون الدوخة، والرعاش، والإثارة، التشنج والغيبوبة والغثيان والقيء، والتغير في ضربات القلب، وانخفاض ضغط الدم، وتغير في توازن الجسم السوائل / الملح. خذ عبوة / علبة إنمينت معك عند الذهاب إلى الطبيب أو المستشفى. إذا كنت قد نسيت أن تتناول إنمينت لا تأخذ جرعة مضاعفة لتعويض الجرعات المنسية. إذا كنت قد نسيت تناول جرعة، وتذكرت قبل أن تذهب إلى السرير، تناولها على الفور. و استمر كالمعتاد في اليوم التالي. لو تذكرت فقط أثناء الليل، أو في اليوم التالي اترك الجرعة المنسية و استمر كالمعتاد.</p><p>&nbsp;</p><p>إذا توقفت عن تناول إنمينت</p><p>لا تتوقف عن تناول إنمينت حتى يقول لك الطبيب أن تفعل ذلك. عندما تكمل مدة العلاج، ينصح عموما أن يتم خفض جرعة إنمينت تدريجيا على مدى عدة أسابيع. عند التوقف عن تناول إنمينت ، لا سيما إذا كان فجأة، قد تشعر بأعراض التوقف. وهي شائعة عندما يتم إيقاف العلاج مع إنمينت.</p><p>ترتفع مخاطر، عندما يتم استخدام إنمينت لفترة طويلة أو بجرعات عالية أو عندما يتم تقليل الجرعة بسرعة كبيرة جدا. معظم الناس يجدون أن الأعراض خفيفة وتزول من تلقاء نفسها في غضون أسبوعين. ومع ذلك، في بعض المرضى قد تكون شديدة في الحدة أو قد تكون لفترات طويلة (٣-٢ أشهر أو أكثر). اذا كان لديك أعراض التوقف حادة عند التوقف عن تناول إنمينت، يرجى الاتصال بالطبيب. ويجوز له / لها أن يطلب منك للبدء في تناول الأقراص مرة أخرى، وإيقافها ببطء أكثر.</p><p>وتشمل أعراض التوقف : الشعور بالدوار (متقلب أو في حالة عدم توازن)، و الشعور مثل الدبابيس والإبر، والإحساس بالحرق و(أقل شيوعا) الأحساس بالصدمة الكهربائية، بما في ذلك في الرأس، واضطرابات النوم (أحلام اليقظة والكوابيس، وعدم القدرة على النوم)، والشعور بالقلق، والصداع، والشعور بالمرض (الغثيان)، والتعرق (بما في ذلك تعرق ليلي)، والشعور بالقلق أو الهياج، والرعاش (الاهتزاز)، والشعور بالارتباك أو الضلال، والشعور العاطفي أو الانفعال، والإسهال (براز رخو)، اضطرابات بصرية، ترفرف أو قوة في ضربات القلب (خفقان). إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب هذا الدواء أعراض جانبية، وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p>عادة ما تختفي الأعراض الجانبية بعد بضعة أسابيع من العلاج. يرجى أن تكون على علم بأن العديد من هذه الأعراض قد تكون أعراض مرضك أيضا، وبالتالي سوف تتحسن عند بدء شعورك بالتحسن.</p><p>إذا كنت تواجه أي من الأعراض التالية يجب عليك الاتصال بطبيبك أو اذهب إلى المستشفى على الفور:</p><p>غير شائعة (قد تؤثر على ما يصل إلى ١ في ١٠٠ شخص):</p><p>&bull; نزيف غير عادي، بما في ذلك نزيف الجهاز الهضمي</p><p>نادرة (قد تؤثر على ما يصل إلى ١ في ١٠٠٠ شخص):</p><p>&bull; تورم الجلد، اللسان، الشفاه، أو الوجه، أو صعوبات في التنفس أو البلع (رد الفعل التحسسي).</p><p>&bull; ارتفاع درجة الحرارة، والإثارة، والارتباك، وارتعاش الانقباضات المفاجئة للعضلات هذه قد تكون دلائل على وجود حالة نادرة تسمى متلازمة سيروتونين.</p><p>غير معروفة (لا يمكن تقدير تردد من البيانات المتاحة):</p><p>&bull; صعوبات التبول</p><p>&bull; التشنجات (نوبات)، وانظر أيضا قسم ٢ &quot;تحذيرات واحتياطات&quot;</p><p>&bull; اصفرار الجلد وبياض في عيون دلائل على ضعف وظيفة الكبد / التهاب الكبد.</p><p>&bull; سرعة، عدم انتظام ضربات القلب، والاغماء التي يمكن أن تكون أعراض حالة تهدد حياتهم تعرف باسم تورساد دى بوانت.</p><p>&bull; أفكار إيذاء أو قتل نفسك، انظر أيضا القسم ٢ &quot;تحذيرات واحتياطات&quot;</p><p>بالإضافة إلى ما سبق تم الإبلاغ عن الأعراض الجانبية التالية:</p><p>شائعة جدا (قد تؤثر على أكثر من ١ في ١٠ شخص):</p><p>&bull; الشعور بالغثيان (الغثيان)</p><p>&bull; الصداع</p><p>شائعة (قد يؤثر على ما يصل إلى ١ في ١٠ شخص):</p><p>&bull; انسداد أو سيلان الأنف (التهاب الجيوب الأنفية)</p><p>&bull; انخفاض أو زيادة الشهية</p><p>&bull; القلق، والأرق، والأحلام الغير طبيعية، وصعوبات في النوم، والشعور بالنعاس، والدوخة، والتثاؤب، والرعشات، قشعريرة في الجلد</p><p>&bull; الإسهال والإمساك والتقيؤ وجفاف الفم</p><p>&bull; زيادة التعرق</p><p>&bull; ألم في العضلات والمفاصل (ألم مفصلي وألم عضلي)</p><p>&bull; الاضطرابات الجنسية (تأخير القذف، ومشاكل في الانتصاب، و انخفاض الدافع الجنسي و قد تواجه النساء صعوبات فى الوصول إلى هزة الجماع)</p><p>&bull; التعب، الحمى</p><p>&bull; زيادة الوزن غير شائعة (قد يؤثر على ما يصل إلى ١ في ١٠٠ شخص):</p><p>&bull; الطفح الجلدي (الشرى)، والحكة</p><p>&nbsp;&bull; طحن أسنان المرء، والإثارة، والعصبية، ونوبات الهلع والارتباك</p><p>&bull; اضطراب النوم، اضطراب الذوق، الإغماء (الغشيان)</p><p>&bull; توسيع حدقة العين (توسيع حدقة العين)، اضطرابات بصرية، طنين في الأذنين (الطنين)</p><p>&bull; فقدان الشعر</p><p>&bull; نزيف الحيض المفرط</p><p>&bull; عدم انتظام فترة الحيض</p><p>&bull; انخفاض الوزن</p><p>&bull; سرعة فى ضربات القلب</p><p>&bull; تورم في الذراعين أو الساقين</p><p>&bull; نزيف الأنف</p><p>نادرة (قد يؤثر على ما يصل إلى ١ في ١٠٠٠ شخص):</p><p>&bull; العدوان، انفصال من الشخصية، هلوسة</p><p>&bull; بطئ ضربات القلب</p><p>غير معروف (لا يمكن تقدير تردد من البيانات المتاحة):</p><p>&bull; انخفاض مستويات الصوديوم في الدم (الأعراض هي: الشعور بالمرض بأنك لست على ما يرام مع ضعف العضلات، أو الارتباك)</p><p>&bull; الدوخة عند الوقوف بسبب انخفاض ضغط الدم (انخفاض ضغط الدم الانتصابي)</p><p>&nbsp;&bull; نتائج غير طبيعية فى اختبار وظائف الكبد (زيادة كميات من أنزيمات الكبد في الدم)</p><p>&nbsp;&bull; اضطرابات الحركة (حركات لا إرادية للعضلات)</p><p>&nbsp;&bull; انتصاب مؤلم (الانتصاب المستمر)</p><p>&bull; علامات اضطراب النزيف مثال من الجلد والأغشية المخاطية (كدمة)</p><p>&bull; تورم مفاجئ من الجلد أو الغشاء المخاطي ( angioedemas )</p><p>&bull; زيادة افراز كمية البول (غير مناسب إفراز ADH )</p><p>&bull; تدفق الحليب عند الرجال وعند النساء الغير مرضعات</p><p>&bull; هوس</p><p>&bull; لوحظ زيادة خطر كسور العظام في المرضى الذين يتناولون هذا النوع من الدواء</p><p>&bull; تغيير في ضربات القلب (وتسمى &quot;إطالة فترة QT&quot;، وينظر في تخطيط القلب، قياس النشاط الكهربائي للقلب). بالإضافة إلى ذلك، ومن المعروف أن عددا من الأعراض الجانبية تحدث مع الأدوية التي تعمل بطريقة مماثلة لإسيتالوبرام (المادة الفعالة في إنمينت). وهذه هي:</p><p>&bull; التململ الحركي&nbsp;(تعذر الجلوس)</p><p>&bull; فقدان الشهية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول و مرأى الأطفال</p><p>لا تستخدم هذا الدواء بعد إنتهاء تاريخ الصلاحية والمكتوب على العلبة الخارجية بعد كلمة .EXPط</p><p>تاريخ الإنتهاء يشير الى آخر يوم في&nbsp;الشهر .</p><p>يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية .</p><p>يحفظ الدواء في العبوة الأصلية للحمايه من الضوء.</p><p>يجب عدم التخلص من الأدوية من خلال مجاري المياة أو النفايات المنزلية.</p><p>إسال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه الإجراءات تساعد فى حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي إسيتالوبرام.</p><p>يحتوي كل قرص مغلف من إنمينت 10 ملجم على 10 ملجم إسيتالوبرام (على هيئة أوكساليت).</p><p>يحتوي كل قرص مغلف من إنمينت 20 ملجم على 20 ملجم إسيتالوبرام (على هيئة أوكساليت).</p><p>المكونات الأخرى هي : لب القرص: سيلليلوز بلوري مكروي، كروسكارميللوز الصوديوم، ثاني أكسيد السيليكون الغروي، تالك نقي وستيرات المغنيسيوم.</p><p>غلاف القرص : هيبروميللوز، ثاني أكسيد التيتانيوم وجليكول متعدد الإيثيلين/ماكروجول.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يقدم إنمينت ١٠ ملجم و ٢٠ ملجم فى أقراص مغلفة. وصف هذه الأقراص المغلفة كالتالي:</p><p>إنمينت ١٠ ملجم أقراص مغلفة: أقراص بيضاوية الشكل، بيضاء اللون، مغلفة وعليها خط للكسر محفور عليها &quot;04&quot; ,&quot;RZ &quot; على كل قسم من خط الكسر على جانب واحد وغير محفور عليها من الجانب الآخر.</p><p>إنمينت ٢٠ ملجم أقراص مغلفة: أقراص بيضاوية الشكل، بيضاء اللون، مغلفة وعليها خط للكسر محفور عليها &quot;05&quot; ,&quot;RZ &quot; على كل قسم من خط الكسر على جانب واحد وغير محفور عليها من الجانب الآخر.</p><p>يتوفر إنمينت ١٠ ملجم و٢٠ ملجم أقراص مغلفة في حجم&nbsp;العبوة التالية:</p><p>٢٨ قرص مغلف (شريطين يحتوي كل شريط على ١٤ قرص مغلف).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع شركة الرازي للصناعات الدوائية, المدينة الصناعية الثانية &ndash; الدمام شارع رقم. 67 تقاطع 110</p><p>رقم المبنى. 3992</p><p>الدمام المملكة العربية السعودية</p><p>تلفون : +966318281919</p><p>فاكس: +966318281313</p><p>الإلكتروني الموقع: www.alrazi-pharma.com&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11-2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inment 10 mg and 20 mg Film-coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inment 10 mg Film-coated Tablets:
Each film-coated tablet contains 10 mg escitalopram (as oxalate).

Inment 20 mg Film-coated Tablets:
Each film-coated tablet contains 20 mg escitalopram (as oxalate).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Inment 10 mg Film-coated Tablets: Oval, white, scored, film-coated tablet marked with "RZ”, “04" on each side of the score on one side of the tablet and plain on other side.

Inment 20 mg Film-coated Tablets: Oval, white, scored, film-coated tablet marked with "RZ”, “05" on each side of the score on one side of the tablet and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.<br />Treatment of panic disorder with or without agoraphobia.<br />Treatment of social anxiety disorder (social phobia).<br />Treatment of generalised anxiety disorder.<br />Treatment of obsessive-compulsive disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />Safety of daily doses above 20 mg has not been demonstrated.</p><p><em>Major depressive episodes</em><br />Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.</p><p>Usually 2-4 weeks are necessary to obtain antidepressant response. After the symptoms resolve, treatment for at least 6 months is required for consolidation of the response.</p><p><em>Panic disorder with or without agoraphobia</em><br />An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily. The dose may be further increased, up to a maximum of 20 mg daily, dependent on individual patient response.<br />Maximum effectiveness is reached after about 3 months. The treatment lasts several months.</p><p><br /><em>Social anxiety disorder</em><br />Usual dosage is 10 mg once daily. Usually 2-4 weeks are necessary to obtain symptom relief. The dose may subsequently, depending on individual patient response, be decreased to 5 mg or increased to a maximum of 20 mg daily.</p><p>Social anxiety disorder is a disease with a chronic course, and treatment for 12 weeks is recommended to consolidate response. Long-term treatment of responders has been studied for 6 months and can be considered on an individual basis to prevent relapse; treatment benefits should be re-evaluated at regular intervals.</p><p>Social anxiety disorder is a well-defined diagnostic terminology of a specific disorder, which should not be confounded with excessive shyness. Pharmacotherapy is only indicated if the disorder interferes significantly with professional and social activities.</p><p>The place of this treatment compared to cognitive behavioural therapy has not been assessed. Pharmacotherapy is part of an overall therapeutic strategy.</p><p>&nbsp;</p><p><em>Generalised anxiety disorder</em><br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily.</p><p>Long-term treatment of responders has been studied for at least 6 months in patients receiving 20 mg daily. Treatment benefits and dose should be re-evaluated at regular intervals (see Section 5.1).</p><p>&nbsp;</p><p><em>Obsessive-compulsive disorder</em><br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily.</p><p>As OCD is a chronic disease, patients should be treated for a sufficient period to ensure that they are symptom free.</p><p>Treatment benefits and dose should be re-evaluated at regular intervals (see section 5.1).</p><p><br /><em>Elderly patients (&gt; 65 years of age)</em><br />Initial dosage is 5 mg once daily. Depending on individual patient response the dose may be increased to 10 mg daily (see section 5.2).</p><p>The efficacy of escitalopram in social anxiety disorder has not been studied in elderly patients.</p><p>&nbsp;</p><p><em>Paediatric population</em><br />Inment should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4).</p><p>&nbsp;</p><p><em>Reduced renal function</em><br />Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is advised in patients with severely reduced renal function (CLCR less than 30 ml/min.) (see section 5.2).</p><p>&nbsp;</p><p><em>Reduced hepatic function</em><br />An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to 10 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2).</p><p>&nbsp;</p><p><em>Poor metabolisers of CYP2C19</em><br />For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg daily (see section 5.2).</p><p>&nbsp;</p><p><em>Discontinuation symptoms seen when stopping treatment</em><br />Abrupt discontinuation should be avoided. When stopping treatment with escitalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of discontinuation symptoms (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>&nbsp;</p><p><u>Method of administration</u><br />Inment is administered as a single daily dose and may be taken with or without food.</p><p>If necessary, you can divide the tablets by firstly placing the tablet on a flat surface with the score facing upwards. The tablets may then be broken by pressing down on each end of the tablet, using both forefingers as shown in the drawing.</p><p><img alt="" width="389" height="185" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAYUAAAC5CAIAAABIjrR9AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAEW0SURBVHhe7d13tJbVlT/wlMkYoxFQEKWJgoAFwYYVQWzBHjUWsEUTU2aZtZyWzJrMrJk/krVmZWaSTBIniRiNhYgNjSAKdgWCha4CIkjvimDNlPw+9/1en987qCQxKO/lnu8fh/2cZ5+2z97fs89733v5+O9+97uPFRQUFDQAPtH8b0FBQcHWRuGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZB4aOCgoJGQeGjgoKCRkHho4KCgkZBa+Gj//7v/3777bcj/+///m9V1uN//ud/3l1ZUNAg+O1vf6vctl3047/73e+axW0dVvrxj3/cdhI++clPYh+Pb7755p/92Z/9+Z//OZmOSsxFZ/vtt0+rgoKPDHFOIHNI+MQnPpGjdIcddvDWIxf9r//6r09/+tNpso2hFfGRjczuKvFRBGh+XVCw9RCuaX6oAybabrvtIsdjBSzvTc22h9bCR46UT33qU80Pta1VIzNSyRVQlUrbXOipYKsgh2WS9EANyNzJbmqRt2EmClpRfgQ4yL5uPtdFT4Cqmp8LCrYeNm7c+NnPfpYgTsNWCdh65tqW0Fr4CA29/vrrixYtspFdu3Z1Gw/jJAcmsAMa8rYwUcHWQpyQwA+D1L/88svr1q3bddddt99++7jrtuqlrSg/Wrx48ciRI6dOnbrjjjt269btoIMO2nvvvffYYw/pUnVNQ1ubpM0FBR8B3n777U996lP1fvjmm2+6pk2bNu25555TejV8+PCjjz6a2iYfPmxLaEX5kVRoypQp06dPX7hw4YIFCxxEsiS5Uo8ePfr164eb2rZtWzlEJRQUfJTYsGHDSy+9NHv2bDS0bNkyvtq+ffuOHTt26dLlzDPP3GuvvbbbbjueXPKjbQFYaf369a+++uqaNWvmz5//4osvzpw5M9c0t3RJU9++fffff38kJYdqblNDfRbNYg4ugjNKmbfhL4K35NRXUB+dqBW0OPAce/ru7eMJn6yh+bkGPmC76VduUEUZIcqVgpo33nhj7dq1XHHWrFnLly9ftWoVL3U6St6dlLvssguH3H333du0aVPRUNXzNobWwkf8xl5aLMcicCz58CuvvLJ69WoeMG/ePPRElgn/eQ2DBw/ebbfdHEfOpXygGOhh865Agaspg7id4QyahmZiFKlZ9AtaFuxphE3cwEZn35Uec5+is4laBT6wbt26F1544fnnn1+6dKny9ddf5yedO3fu3bu3nJ3Qrl07NMQb67MhDmyU+pptCa0rPwJ+4IDKQWdrySwgSeYciEl6DIjJtY43dOrUydHkmOIfuGnXXXeVKvOPdPXWW29xvvqPn94Phng/vyxoEbCDEHkTllEfDuIGm99lzgNz587lXXJz/sbr8mHQ4Ycf7uTr3r27q9nOO+8sFeKZjq7K2cBAm+9/G0Cr46N4T3JmzpENziNImmTOudMtXrxYCi11wlY77bQTd+nQocOBBx7oyOI3sug00Qleq8+AAgOBmjgrVKMUbAOwrfaXsAkNcQYUwxlsd+r50qJFiyTgK1asmDFjxsaNG13QtttuO9TTs2fPfffd14GnE/n4jjvuqFvN0VDaxkUjV8I2jNbCR/Z1MykuD7DT9QpqcBMmevnll51jyauXLFnCXVy1JEp8aO+99+ZP3bp1w1bNzWruWNGTx1BSXgVRqD/3Clo6eIsSAdn31MidV65c6TCTDb300ksybqz09ttvy7J5jhtZjre2bdtuv/32GlbeEkd9P96hwAOh/HxtW0C1nU0HTe1jndR4VZ1mgC88RpOg5rXXXuNSuIlvyZs4GZLy1p2uffv2+KhXr17Ot1z78wX/+FYGgtQoNzlOC1oEuITSDmYTs6eQk4yT2GuM48RyEcNE/MQjh3HnQjqOLnkQDuIb8mvnGdLRlbbpnC+R609ENRR4S5MXvuOiFd9tq2hFfNTkSjUPiBPUI3ufV9Bc+3/rPZIdcbjJnS4fhMvDYc2aNcnA5dsYKsQkdeJ52IqTbfNutM0D72xCB2pwkAwI+yxYsCBu4C4mrfYK43ADpxRP6NSpE0r6zGc+I6mpfjeAL6EhfpUDL0dgBBSmfpPfIogfvlvextDq8qNqI3FNnEBNKmOKyN5WzhdWiruQo69GTu4MfOWVV3ghhiJwSq65YsUKnupa99nPfrZr165OxX322Ydrys9zACYnr/Vd0JJg46Q8SZDzA1ngBhzJUWSjsY8db9OmDT6SNec6Fo9KmU44z3teuOo9DfSMlVLJG9ODRz1sq/f91sVHHx54yeuvv46eZE/r16+XOsnYnZwLFy503PGwXXbZhb/K2/v27avM6ZdX8T+ZF4erkikdKiPX/5J3wYcKqQ2mUKKYao/UuIhNmzZt+vTp9nTdunU22nkj8enevTvqwUFKlJRDqGzWB0bhoy0JTpxzjEMjJnB+SuMlTU5U2ZNk3rGJm4444ohBgwbxZjWOQbe85i7qYGuqQ7Xgw4D9qvIRstJ54CTIMbBhwwbsM3PmzEcffXTp0qVhKLewPd5BfiImA6ruVjIXbdO84AOg8NGHAlblvsmrCRjHnQ435RvhSml/+/btBw4cOHToUHmTJlUY1AOviZbi3x8GGBzdv5vxbRabu4CPHTv2kUcecajIjw477DDbFA5ynOQnqrlPpVXBFkHho48Ccn7enzu/dMltbs6cOePGjcNQQ4YMOf3003v06JEPFKhVJzbgMjWFkj5sVIeBdFW+4142YsQI+WyvXr0OPPDAPffc09UMDbmO2REUls3KVc5+aQ5ht6Ds1wdD4aMtA36MNUIc3LG5tvZFASl980MdpE5ucHffffdjjz3G3S+//PJDDjlEPbfm8YR4fMGHDf7/xhtvuKblQx8pzzPPPHPLLbfIYV2ozzjjjJ49e9b/8MEG2bvqY773hB3kCc0PBX8MCh99KGBVTqnkuKEnZ2k+K02WFJ5asmTJ7bffPmXKlA4dOpx66qknnnhixWX8vpyxHyrsDmvbJvuSa5c79aOPPnrDDTe8/fbbl1566bHHHmu/7IKMCQehmPqTxgY1S+WvQWw5FD7aMuCvEbhsvJZhuSyH5vERokAWANWPYNatWzd+/His1K5dOzGw33775bNtzfWZVjmQa+oFWwybML57tFz1uuuu69at2+c+97nBgwdXX7uvNLOn9rcQ0IeET/7TP/1Ts1jwJ4CDVgglEZyoyZIqMpIleZQiud+pDDEJAPpz5syZNGlSjx49nNU71H77vz7tpxChYEvBRsSqKMaVTWaEjDp27HjmmWcOHDjQFthBrzbZBVCfx2xiZL1lr6u3BR8AjZIfCdRcZHiAdEApLHPBicI2gCrNsTplHDffLeLZ9957769//ev169dfeeWVRx11lLfq7c7rr79efQKloZoqPETRZz7zmcgFmwfTvZspqh25+uqrx4wZ06lTp6997WuOB9dnduZ+8Ul4vzAJo7VcxAJWmoVY5taNuEbJjxJjWIl1yFXcVrHXQoFushYQD45QHkBIWTkBv2/fvv1nP/vZJUuWPPHEEyr79euXEPKKu8QOTadzDU3dlc+8/2CwNmOyG1NHZk+ycvny5ddee+2DDz647777XnjhhfJTG6EJZW/zqV+1g+9GtRctFBVHW2PkqmaroFH4iIuIVUbJBsdvOMQ2sN+WYC2ICX14zKJScvdwCtkFoUuXLlKh2bNnz5o1Cw3tvvvuVZP0BjEIW21dv2lBiK3iWsCYEIpfuXLlyJEj77vvvj333HPYsGEDBgygpv6tt97Kxik3T/p0mqWWDCayEEG31TOARuGjJk+pIUapvKH5dYuFVSjxUZajtPfPP/+8XXfVUp84ee211xAQ7L333p07d543b96UKVO23357N4hEiE6YpeqQHCuRCzaPWD4y74oBmVRmdOutt8qM9ttvvyuuuKJ///7ODPUUqsgkrF69esOGDfV/I7Qe6a3lIvl7Vg3xtK2IBsqP7D04uKqUobqntFxYl8MW0VhUGGTFihUjRoxYvHhx9+7d27RpEzULVyZscFDHjh0XLFjw5JNPtmvXrk+fPnrQnE7FQcoIBX8I+JLyjTfeYEPhx4wo5oYbbrj//vv32Wefiy++uG/fvhTylpCShZ0ct912m4bU1Lwb6blFI44k1phlq4dbo/h0bAH5QTjrKDefKrcI1Hij2cgyI6UFSovGjBnjXuaR7NamMjHADlzcxWH48OFt27a96aabxAMdr/QTnZBXvVCwGTBpysq7Xnnllf/8z/98+OGHe/fuffnll/fr1y/RWB2ESsrMO3HixIceeig9bJPgUfEua8/y87i10Ch8xC62f+nSpYmx8NG2ATGAiawrxNS+fftTTz3VXeyxxx6TBPH+ygOikxqUdOmllzLL7bffPnnyZLeGWAbCa/VCwfuhMhrDhoyWLFkybty4Rx55xDWNhffdd9+8BfZ0f8E+BKX89KmnnnKDRli1PrZBWGZ1EAIhj1sLDfT9o2eeeeauu+5yLnXt2pUbEV599dWW/vuKGzduDB9hGTtN4PcSn4ULF06ZMsW9bP/99/cqp3FYOMHgitetW7cddtjhpZdeevTRR8koLJ9ihLYIKQs2j8pcWJ5HyXeuvfZaNDRs2LCDDjqItSFBSI1gOwgqb7zxRj550UUXHXrooe9nasrNUstE5r9u3bp7773X5XS33Xbbut8gaSCHfvPNN8ePHy9lcEaJxtdff736eKWloD7TiYBBVMqEU4N3LBMfnXnmmbvssovrwHPPPafSq4QNCImwMHoaPHjwBRdc0KFDh3/913994IEHXnvtNfU5xyp4pGkUyL2j+UXrAxu6/LJDHnFKxfUely1b9pOf/MT91zXtkksuSWbkbe4pYGsiwIMPPvj0008ffvjh/fv3r1IGPesQ3njjDWUqjRjBW/WRGxAcg0EiN/lK3b3MUTdhwgRpeBxsK6JR+Mim7rTTTu3atUNDjOIRTyOm5tcNj6Q2cVxyfNRCwjJx4kSFvVe6BRx55JHPPvusS0GiKExUqfEeNZQdziipZ8+eIuTqq69etGhR2C2uz0TU1Gib0PLYCikpS2Y9J1lFHwySIGTeF154ARO5I3fp0uXKK69kf7b1Ng2DavvWr19///33a3XCCSc4NlTWNrDp1/qjn1/0J4tqI2Y7NOe09R02DprWWftoMo+cBCJbyNq1a/mq4z8/8039VkGj8BHX2XXXXZlj1qxZvEGYsV0u/C0CZlsdPgkDwo61/74mTqAynAUqOTRf33333UXI1KlTKyfg2RCdkJoMyynt1sA+7hojRoyQUumTrd56662YiMCfKm9Lw9aGphO/9qdgm59rEHUsj/e/+93vjh079rjjjkNGvXr1ys2X3aIWhI9Y/pFHHnF5YXZnBgvXn4tsm82y3Xp20wFNsFKl4DFy44BZ6jmo3kpWsWTJkg0bNrRv3z482/xia6BRPj9iKTs6ffr0GTNmcILOnTuLrsp8jY/aXn+CL5r2qlWrsIxEZo899vAYx41aKAMxUZYMOm+5/saNG4844oh8zBS19MZpeHaE7t27O9gdwtOmTRMqIidXfV15y3RAEGCatPQP3T4ArJpN2IocIzNmrHHXXXf98pe/ZOShQ4eed955e+65Z3QosJgt8Gjj7FEaLl26VB4qWbj88st33nlnlXqOvpJ+tolgO6677rrZs2d37NhRGmU4mukH6DQOWKaaklVnLSr5jwmPGzdu3rx5xx57LKbeuklAAwU860gZxNVTTz1lp9mr/j7f4EjuY/JWwS8fffTR22+/3bGTtzlRK0+15dQ8HnbYYf369ZPvPP744w4or1KfVnrj9CoTM/vuu68IOfvss1955ZWf/exnt9xyC4FyTnVOZg40t64/bS1URgtBR5Yz/vCHP7zpppvsyMUXX3zFFVfgdMkOBWDYirizQcCko0ePXrFixTHHHIO5Xn/99dAcfUNklwkZbsKECQ8//PCaNWvyiPsS59DUV0PCQiy2cjMO4+B84oknZN+9e/cO1W5FNNDP1zhKt27dXF7wEVfYa6+9EoctAtnd7LS7wAsvvDBnzhw1ffr0kcWorGk1uWy9s4oHVzZ8xCEkUzm6eYyyXo2sZ/U77bTT3nvvrVy5cqVWTz/9dIcOHRCQIZqC4J3v1/KqasTWA/bBF0icHZxnmOLWW29F9AMGDLjwwgtdvlxGqLEMBcoR1ITHPdqde+655+abb0ZG55xzjt2p/8Jqk33fgRph/NOf/pTl5Vz5OmU6qak3HEK4FWPmDEuNJTs+hwwZcvzxx6vZukHXQHzEZDxA5uxKIrt2lOU3G1sQLMEG21GuL+0XDPn/jmx/HDrnDyGP3Feqb8mYRX6Ej3bccUf18RslJHJAvcjBPj169KBJ/5lnnnFZcPjrBElRkFFq0oJ4fAvC8tExcy1cuNAFZOzYsewjLRJpBx54YFIhfqVkn9ifrdKKeRl8ypQpKMzefelLX8L7NL2yp9VtDiKvX7/+tttuc3E++uijjzvuuPhtRqfTNJsGQ1YahIzUyP4mTpz461//moueddZZ+eUkCmmyVdAofGTXc9GQIq1du3bSpEmOOCmSMItCgwMpcMdsp53ebbfdHNTTp09/+eWXpUjt2rWzwPg016dPUEPW0JLJ9913n/r99tuPHfRDOYiyPil7pC+cZNeMI2YMAVhp++2351XaVkO0KiTepNg8R9rCmD179rzqqquOOOIIhmIQTM1u8TGPQD9ID1JaV2xl/nYwZrGD6p0B6Majzu0L3tHPzJkzr7/++u7du+M7e+1tgtwhUXFTrddGQbVeQmqQkcvpjTfe+Oyzzw4fPnzQoEFq2CeWjM5HjwbKj1jBGWWzxaf7yOTJk5cvXy4XsLVxo+rwocasSr6SQK3qmzqqdRVBE4h+arYIQiXNDzWEiYylPlNq27YtSh0zZozAcPJwbvVRoE+wLjXWy4OlRbliYK58LyZL4NmJgbg70M8rt0KR1qtXL6vDR0kqpWO6ImxisWCL2+GjhxXFvNYSalYZ+6xateqOO+4YMWKEuEITF110EUeyC2kYTYgFdJJWcSEWGzlyJJe74IILDjvsMIk5u8V0sTyZgJL0Y6BrrrmGi15xxRU2Sz/pPEcOtZBR+Ev/edzixo8pCJmnxwxhGuSMRQYKoWM1Zpv5SMl/8YtfOMy+8pWvuKnxz/hMettaaCA+AvZlLDmRuGLBp556Skos8PbYYw/2zQZHzSNk71nQrtsDj8oYtCqBZlPvWwK2U4cGNWI6f632q/lexbO9ynBYxgYvW7YMy6AkNyxto5lIIGiuFSGfU1CeP3++yxf+0hVUau+3BImSlMoVwyVl1qxZL730Ej4ylrZ6TnMe6bHJXls0HrYKmEJpl9lZgBF4BTs75K+++mppkauZ25YEh02YIq3eDcbRCqOxiX7cWfIbJEOHDsXyRonFoqmMzJ6EUaNGjR8//owzzpB87bzzzolz0CS7T2Dz7LUapU7CC+lni6C+N3L1qIyAntjHNLwyybiuJfDYu2tYtGjRueee68q5++67m3P6MdXMeaugUfioyZw1g3IvO5f7CINKv7maREmUdujQwVs+JNQ1Yes0jMyIkSts8rhFYBRjNc31ne2PC0ZQRo5OvtAxbtw4ibHl4FluYVHx4OrAtCK3LWk/V3j00Ufl/LJCjh7aUll5/LvBIIbAd/klmyeffNKNY5dddpEaeEwPRuFtNDfTTwtCwp4grnCKR4z/7//+79Iil47zzz//gAMOoGCxoeP3A7PE8hxMVkX5nHPOQWfZFE6YUaJpNwls6Iy85ZZbpLFf/vKXeanKqNnNmDpyTF39wpNNJOTtlkXNEzf1c5M3onrTiBtkAmoceNdee+3YsWORNfI97bTTOnfurAkFC6FQLXaroFH4yE4zHIvYVJkRP5MW9e7d21FvU0Wp9JKV2S4ZOPNxRBuvFQvGiJVNY9CUWxw5Z4yIODLhjOuVSmU8QOlVviXkOF2/fv3BBx8c74xaPD4yget06dJl9erVU6dO1Xb//fcXKpVnvx8MRIe5WAblickXX3xRouTEyyUx6ZtRDKfMcC0XIaNY2KqtHRldd911Vvf5z3/ebSvRZcmMzxpJUt4NduBmqNy+SKwWL16MyAYPHszaNle3dLKnUTai+gULFvz4xz/mq25qnNNumoYmsW0axsJhyXnz5jmERL7K1G8pcDnDQR5NL3DycRtjWb5H0yDHu5YuXTp69GhkNHfuXJSNfI877rgk5uZPOZ5W9blV0Ch8FKvFFvwslQR8xMOYWKCipGnTpgkwbuSAYnFNOER8gn5tg5qtSWDiyFDV/4nQp80LHnjgAadlr169OH3liBwl3kAmQJ8+ffilQ1jKgyPCMuord88quA7mkgY6wZ555hk5zt57702NgkHfb/4WHrcjCw+TUWI0hjIc61EQP+ZDMLdMrOUipnAS8AHGEWDIyKKuuuoqqQ2vYAoKMZf1vh8fAYPYiJEjRz744IPHHnvsWWedJTjT3NvKGxPSZLfpMWPGcMITTzxRWuEV/4wanexmLKxm5syZIl+l3bfj8c8tiGp6AbMAgVmUnFPqZybg0YkuIcofn3Ocf+ELX0BG+FQnQMH8K0NpG6/bKmis+5rISXKkJnZRMrFkoW/fvjZboNpp916s5JUApszosaAeWDZCVWartpSJzcGIiW3e+dBDD8lEXK+q/jELOfCYKdGZM2eOy5RrVPfu3fMKvApZcAvLISAR/bul8v599tnHo8lnIe8HI2qSEdlKRqa3GTNmMJR5igfdphOohm6hsASWt++o5Kabbrr55putV2pz5JFHirQskCVDEJsho3jXI488gjXy67VMzVw1IzUjmrEYA951113oz0DDhg2T9cRLoxYaIhhUjUc0N3369IEDBx566KHRzIiELYgmz67bWeAMLJO1e3S23X333TfeeKMM3eokROedd95RRx1lsXQoaKgfQjrUtv7xo0ej8FF2y6bGJ9R4ZB01LGtH2V18DhkyhC86o+QmMo6VK1cm/jVhX0Bn2aHYNF2p2VIm1mH6VEr1JT6rVq2SyDiZKwVlhstM3njjja5du4oQfCSdlu516NChptvcW5St1Jlm+cgL20pwLEfP6gnRf08wnVYEXbEYSmIoZzL75KcBcq683Xw/LQXWa5fvuecefLTrrrt++ctfFvbV6ticEHkz9zXb4f6iBzoXXnjhQQcdpLJpM2qITgX8Yu/uvPNOuecXv/hFSWg8ylmipE/BFmS76U+ePPmOO+7o2bPnySefnI+K1ZuzWW0pPwR7najJoB7z0apHlwlHGhq65ZZbZs+ebXpnnHHGKaecInzMJ6RjMmlYwTz1FtNtLTTQfa3asOokUTJlDCTMhJaruNgeMGCAREPQTpky5fHHH+crs2bN4l4vv/xyPmKsN2uMvonpPzD0k4zG5pkJQsSM9pjz8YbkKdnXeKH5I1Ce6uq0du3ahx9+2NHk1mYhiRaaOgzzgiGUznw3QWmgez7yopPR3w1tuSABLyuzaqXhnOEsA6YnKUugNrVpyWAokS/SXNP69et38cUXs3x+jhYrMXvsT95MfkTh17/+te044YQT3L/0SblqCBW58MY1a9aMGDFCrhHu27hxI5tHgX5KiN9yiVGjRvFGmcjhhx/uLejHEN7W+t5i0HP2lBs4F5cvX+5GJo+TnUn9hAM3sLozzzzzmGOO6dKliyCibybv6Qlsu9U9pFH4CJgpO1e/bZsYyCPnE6K4YL/99nOPc/jzA7cbVzm3p4kTJ4rkxYsXcxq96RN0KFyrrthdkyY3+b8kpR4op6TDQSu10FCE8Aj22WWXXebOnWtoxNGmTZtQQzxVJxmRTFnp6mSet912m/udxCfRQo2QnqE60k37vvvuQ0wHHnhgpqFbyl4RMgRZz3kkZJSmXmo6e+yxhynJkrC23vbaa6/0rLeK5a2RZarRtxZMCcyZXL+EyGbobSbs0MJEbIhhL730UicTuq/eso8m1UZX0JVXFlup2cSf/exntu+kk06S76hnk03skNGltLIMzCUzGjRoEEvKPdVntsqY3SSZVyf333+/TEq38hHxX5maTqZB34RTUzlVFpu3HqFqCE3WqXPFgDLGsb8TJkwwonsZ4Te/+Y1zWnS4lA0dOvT444/v37+/R575brNsgmrorYgG4qM/CmznioT+UZJzEjf17t1bwHMLTGSTHq3BrWfBggUOKyzmlVa2XxnoJ0mZbY5jkQlKnXA7NV5xGgJH5CKERDXnJnM4bjFjxoxXX33VYajzNFeS+RA5nkRZh+plSS+88IIUycVNfYJEfc3lmn41X4dqlDNnzqRsCFRiRG/1qQmYSfw1jxWaTFMD2Twdibjb8rmpVbCSVuo19EjHrAxtDomKrQITiFBbQRPyGK4kZMIEbP7Tn/5Uxmevv/SlL/Xt25eOem/tlyXEIGrYyiuL1bkyZ5K3ZAqExx57DHHo5+ijj5Z3pzJ0oK1HJVlXmEjGccQRRxx55JH8rTIUBU3ouI+HibyyszfffDPPPO200xw5+gnShFAZnKCML2mrK0JGDKh5NEpmApoba+HCha7h7oPYR4pnFW5kdtNe21/3Mhmc2bqBOvbsfnL25k4bHi2Vj+IKEXCNPELezkF5mF0RwO3bt6cg054zZ87TTz8tb3KrF+EvvfTSunXr0BAnAJca28wR89mN9ASLyXWRRX4UCvEeIPASI2pIWbTYbGnIc889p3ODmoaaJgesuSC1+FmgktMYiw95xV2MHrdWmSZGEVo4CExVMODTDRs2aJhbCf2My/vjsrXRmlAbpBkeDYHdkha9+OKLQsUFEGUbTlsNdUWHnKjYKjCHCJm/WeWRQUwsRlaqkYTee++9UmBLOOeccw4++OA08ZYd6LNJrWlTn/rJMlOqYVUKHlesWPGrGiQ++jnssMMoGyU20Ty7FtuKfPzC/pdffvk+++xTP0QUyHxJvWk4k26//fZJkyadffbZQ4YMiVUzScrVBmlL2aMp0cEm48aNq35eTCGaSq1MxkWMzuOPP85tEBBlXuHyiJvc/Z3HCEgedOyxx6IhTtWtWzeXBv6jwwyXFTWN3fD4Pz8Ub0GIQ0S2c/EMqDYev8hmXeaBo9g/j3yRF9KxW+hGqg+2Dfugkn333dfOjR492vZ/61vfkujS1HMcmqDUM4Eal3IoURDzso8f//jH1L797W+jRcPpPCxGIa6gCZn/mc9PfvITQ3z+85//whe+IGmiGdcBcRV/JYwZM+Y73/kOWW/C75hjjuF5hqNQHa3vCQMxghF1Qp8wa9YsriwpEH6OUKkcHSbK1SOrS9uPGGaorCIwwiYwf8cJa0h7hdy5556LkgSzOdtHCjqJkasNamr2DrAJIzAXQSTnJyG4Xlf2K/+R0SYmzY5wmJ///OeI4JJLLjn55JNzHhjLJDNQdo0lPZrAgw8++MMf/tAB8M1vfjMfY1O2fU091pB5Zneaqz72MRnf+PHj//Ef/9HhhGKWLFmyevVqLsRR86gfdMnZtHXKuqjqnLu6bMqyd639FcN0RVPP+ofUQJNNa2h+bmy0VD4y7U1MbLOz/VU9HTsEBEzkHOORtll+5MzBC+vXr7fTAZnDOegWL17MDy677LKLL75YJi9o4/R04q86jMfrlpcYkaPceuutP/rRj/AL36UmzsNZ9a1MT0PK4gHRqOeF3NdwXCorSpm2gpDCIYccYhr57yEl4aeffnp+wU3P+tQJfVAT6AH0kMNcaBmRgkGFFraV0Dm9TzzxRKcrBUswq/qw+SjBJpl8bRH/fxVWJ9pNzL4IV9cTlaYNzv8qTwEbhG4sWVdZqUrNwykxPsgQ8+dHkLsMWgqM4r/61a8KbM3Tij2VBtWbGgx+zTXXyLjdIerJKAqUDRdNr+bNm/f9738flXzjG98YNGiQehOIVTOx9K8tITtOQDe22GlhUSZm1/gnfVOKX6EbHJSfyVIAj5jLfDKugYCg59QExvJYX9Mi0FLvazF0dj1uZPPAXtbeN/u3TQrkwzaS83Xt2tXF/oADDjj00EOPPvrofv36SRakQnzUKzutrdNJGHiVH47Gq/hKzkM1Okycq+FbnF5sL1u2DINwIF1VvgiU44j0dUKggx+nTp265557mkw4q96BMtb06dPFz6k1OAnx6ZO1/4EHg3hEUroyGUaoGlZQaTgCnbxynMoFDD1jxgzRKL+Q1evE0NHcWjC9apJNsVWD5Svd0a6//np8ZPvcrWRGwjI36+hXtMt6VlF1olSfdeEIuZU0BCMfddRRF154oTSTJe2RFCk/D4mm3vTApB7Jmthc+s6MKFTzVEaIv5HNU/p51lln5c+PqEkTk6n6T5NUxiVMbMKECfSty55yBsePy9dJJ52kH4J8Vg1XdC/LBwJcVEP2aZpBDR6BkJ6VqYcMlLFqIzc6WiofMXQsbqehMncqvYXqEfiER5o2UgTKNfgrP+jSpQvS4ZSSDkAljk1BiyzEqgB2juELDasRq90lp/TWeYWSeDnvd6J6NJC30UxbQipBt1IeFEO5bdu2WQLnpha+k8HdeeedYo9r8kUzcUlxPC5cuNAokjhZm3kmHkDDDBEYSFtBVdEikHv16uUoNi7qdKRbuzDIZyvNSh8tNpk2QyV+CC5WN91003PPPScg/+Iv/uLII4+0idZVbffrtb+PoXnoO/3YLELsLB2ePHnyDTfcgNFsMbJgTBdqIf3888+/8MILdj8fqGWDql0gyFnkkoZ2GLBbtXEV6GsF9CdNmkQZmwwfPhyzVAQU6JNyttWmeJVVSIWkbDzBzf1zn/ucBQ4YMID7mZJN4UJAsOkmwCbpKqUlpway8MAoHqsaQppUNQ2OFsxHyndbuWkr3oHHeAxs8ki2T7bZvvIMb7mIelTlCMJETz/99Jo1a0QvP46D0snWVo/cLpeFjKshEuGaMhEMIubDBSIkA+VyR5NAh+aCBQukZghCV5WrUTBEPrzMT21zYRR7rloYU/Mnnnhi9uzZ4g2HZmJKoBaQrSh+bJIezZmagZLBmfZvfvMbiZKxBMDW4qNNYAtCRj/72c9uu+02NpSeXHDBBWyr0nJiTHO2EIeKdbGGXYsBtaWQtcyZM2fs2LEjRoxQw4xiXjpsNzX3lknZ3xY7RbCSfuIJXin1KdlhYRkK4xgoPkPNEBmLDOrpu6ovX7788ssvl3d7lcqqQzXK+APYDqXMS/578803ozwNZcpcwsw1See2zx5p5TH8pRNDp0OPlaaawLiZUiWnvl6nwdGC72u/18rR2QzoZEeV2em4Mh91n3K0OuukyjY++sIgrtDU+zuMFhn0IN1wKZC/aMXLVWoiWgiUIwD3Ah7s8MdcnTt3zriGiLM++OCDUgP3x2HDhvFUns29kta5uTiHHfJiCWHJcZyiGI2CtnR0UlFh+iSbBtkchJOhJQio1rgmIE0z8+7duzuoCcailoavvfOnVP50VEESQee16uYaj2YYrlm0aNEPfvCDO+64w1VFoMoackOpJq/UMAvMjgBZJ6CeHeRWN954I07BRKeffvopp5zCRHRo0lFa+8svv+zySzkZk66qnTXKddddZ2IuTexvYiq9pcM+MbIaM1H5y1/+8qGHHpJ5yXFCKNR0S9ZD5gaapP+m6dYSpauvvtqjrM0Q9a80j6y0nAiQHqrHd4MCUIjQXNui0FL5aEvBSZgtzC46tZR2HZtIkbCSQHWfiufRaW72LiRU8AUumDt3Lg/GGg7hNKkF3f8/rwJj8WMnf9++fbm4HijwP/cIseQOddlllzk83UqSCKS5aegWY0pz9tprL6SJAV0SkZcDlpfjFPrV4UxQmpuZGMI0yDxetGiuFdJBfy4FYjI/daaW4CRn0D8dxo2Fg5o9mqAyMyRY+0svvZRcQzozcOBAlsG2aUKnKilrGwFMWNk0zMc+JuW89tprsYma884779hjj3XVtS7LoR+bWJ0mUkvch7OsHSOoN4HYbf369TIXFsZHOQa8rYZrGuYdzJ8///bbb9cDysNr3oawgD7YjjRReiRk4bb+vvvuc0HDYvLxqj6tslObjNUa0OoWvAly2+I0Stsv1LkjNnFvP+iggxYvXizZ8Yp78Y9EznsirqM3GT4ue/TRR5cuXcqr8rbet8gR9Cng8YLSBBIwa9euveaaa4TlqaeeagJecVYsU7UCXeEj6QOdr3/96+3bt7/rrrv+4z/+Y9q0aSYA9BN4UdZ5jlz9CzmCheBNgnjIH04ePXq0Sli3bp221FwGqzlvcSTeIrODEdEimcHzZdGTTz75wAMPzEWVZv3y8Ti+yIqCzNMyH3/88X/5l39Br2joqquuGjx4MEbLH6gBy1emNzLDYr3evXtLMzVJihr7mI8ZklH8JkbwqG0cBpwHJpzPfdJ//cQMVPmAt+QQvfNjwoQJFn7CCSfIwSvN9JDywzN+I6O150f8wMYDD0NDyQgSzFJ6t6Hnn39eqp/LV+rfD3rQjxDCKVOnTpV9yK34XFyQQuVzBEHlRrZw4UJ5fo8ePahR4Ka/+tWvnJxHH330l7/8ZfFAX1vKyjRUYxTKHs1WFqa5R9mcQY1l2nIKaokZDalpoq0mqMojNbSFfdTIHVCPSFbpEicpkJFhK2e+5lsKGb2SocnotYUwu0migzlz5kgMXaO+9rWvsTmbaGJW1ZKzqHCuHkzSY7bMErS95ZZbyC5o559/fp93/meXtFKfTgiRkdoee+zhij1x4sQXX3zRFqMGM5EyU3ONdSowiNRJTUZRX98DY9ov/eN0maZtsmV6MLeoEbJxHi0kpRrXSbt8zDHHOFFyGYRar00g69yc9R/HaD1o7Xxk+/kTcDhQw/mExCuvvOLVmjVrHIB86IADDuDc3Cvu8p4Q3vF4/aAGbte/f/9ETuor7yRQuPvuuxGWdD23iWXLlj3yyCP8e8iQIdxUeISP+CWOI+gkqI3WDPWiyNUDB7knTpo0Canl5zL6pKy5+RMyc5UeVSZyCF4tWbJkxowZJmAJ6AwTWSzlMEVtnC2ATMDazZmchUiLchuaPXv2mDFj7r//fgQhuzH/KNBkTyVoC5kS0rRMqxC0v/nNb0aMGPHEE09IZ4YPHy7pkPsYxduMmB7IQWRbo9SJCUgtXXtlmqB/r1hp+vTpHCAZVprEXFUP7pUua/369ZOr5lKfgUI6xq3MbpIEb9Wj3VGjRiHT0047DYt5a7hogi3IApWtjYygtfMR8B6OQsBBjz32mOz94Ycfvueee/CFY3PRokUrV64UHs7SzfsHlwKeJ5j1wOGkOdw9fhYdAq91K/ne975HFjxOYFck0Xjddddptc8++1x66aX77bffxtovkXNKDhruoM/F00+gJgqSC/2YoSNaV5KdsBimMyVyFcaaqCF4zMIJMgXpFQZ0x5w5c6bFduzYUbdbMB4yeWtXkgP1hjA9901cLLwx4P7772/5u+22W6WTEszcbB0YwLBqWPLWW2+944477BQWu/jii1GzRVWmSyeQHoylrB7Nh6ZMFrthH7mw+bC2Siwvz8V0bGtT4iGhmLTVlZva+PHj81saSJyOEelUyhkoNbG/BV5//fVol6B/q37qqaeU3EbPruFRC39VY7UetHY+4oicj/DMM89I+NEQAhKo+Ym409KFiPfze0eu3CFH7rtReSoX59O4THnUUUftVPuCZfwy5XPPPScRkK5zdKOTR48eLa959dVXZWEXXXRRz549OaXecswaMRcBPYOBKugtAUCNx5seSkJDvFmcrFq1yogoSejGy8GrKjYqd1cjJUSgKEklOkPNukrmsqWQCesfTExAGtEaf/GLX7gxiWcGt8xDDjnkuOOOUx99yMI1AY8mz7b4+t577/35z38ur0FeX/nKVwYNGmSzWFUnzKIHagT6GuoBgxAyun48xg6Wj4ItFqnZDh3aDpc1Bpw1axbWwM6YwvSaZlAj1vQwf/58tjr00EORYGUr4+rQcOSo0TcowcFz5513jhs3zqXYZpmbnZUhOgYkd9Jbsv3iaSaW3W/qsTWhtfMRl+UEY8eOvfbaaxcsWDBw4MBhw4Ydf/zxqOHEE09Uig35jgNNAPAht4nmlu8C5+NDtXD7hDTeAXvQQQclja8UEJAUDPHhOMoCEln07t3bpcCgQ4cO3bP2G+TxRYJWZDFGSD/qIaMAHdCz8PZW2OARnXjlwMd6ch8z4eLeRp8gQkxAqSthiQusKz/8lgsYKHFovWm4RZAwNoc8WjvLX3311bIMiSQScYc9+OCDTznllKw360oTRlBDsEz9CN0bbrgB6atx4T377LPtlLVTM3mV1kWomar54xsl2as80owcQmcBd2d07DDAO44fQyBl1iOz1YEHHuho0UN9W/dcTIpATdtwrMedYtWMHmUgY3wLlMpZ15VXXulWns+P5IP5Ci52w0pGRK8unmne2rDpFWBbBT/mK4Q4R4R41c033yxDEXhnnXUWBhGETq18gMIRxQY/c6FwcqIknjRgwACuyeEoaM6A+ommGnDvuOqqq7CMQ1uce6uHZGFydfdBlaeffjp9uYxI0JvRHbA008Ofjg0bNkybNs0FUN4nUF1kECsKMETmmTiMTYCMFwT56tWrXXxMWEPTO++88/L1HDrVGhPztXZ/BIyoVYxvO+Qgo0aNEpzuO7jPXUnMI2XGYYpsE640ViaZ0ZVoyF7INZA4MwpmmuHZPx3sZgiZkXTV4WEaEiVJDb675JJLlAyFRu0XY86bN+/v//7vEaIrtjmbRjZaaaX107aK73//++5lEjFuxoWoJaWKMVlg4cKFMj5mx4y6pcA3apNqRWgt+RHigAihYE5Alm/fdtttIva0004Thy5oXjmrm9rUkhGRwzPUS6SFpdNMukEhAaOH+JN4IHBEpcCePHmyREOoJE7imvfdd5/jUT/YQSImkeGdTkIpEjWzSle1kf9U6Aqxur9I0NxAHeNI1s0i8zRtk4fcmFSqMRP6AkNWpZXJi3nhYfI4Qpm1gK6yoj8cuRdndWvWrHEGPPjgg5gOB8kL5CD9+vWzBd26dYvxo6kEk1RpdJr5lM1szz333OHDh+uBmsfo/+nIISFbMZMePXrsVfvDNSqRu9NIfR5psh6GNRlDmzzuMA01ZqsHlR6pqWFhbV0GNUSgdoEPxOYUvFXaFFltnz592BZTo0Vs61CMTutBK+KjbDxHyUGtxtmFIObMmXPGGWc45bgRUlDJVwgUwBHtEWXwTu7YsWNHsrfAI3Wo2wQDIZ4qmZo5c6brHpfSVg8rV650pCM+j/mLWeI5c6jgMf1sEQhgQCtYyYSt8dlnn3UXcCXh5RnIEhLnaNQkVdJHo17Nnj172bJlmFeckPEF6kTHNFkvyeMfhfAXE7kJjhw5UtJhJgw+YcIEc2ArZORUMFz0GcRGZKdiVfOXGckuBT8mcnigADp2QQ9p9afDiJlDTBSbWLgzJn8eL+mb+ow7ZcoU9Nq/f3+TT012k20tNjUsrIl+jjzyyPxuo54ZvPIf+siazLD6Wbp0KZsffvjh7PPH8n5LRyv6/IiLxFd4ABdRs2DBghtvvFGe4lYiO4iOV1GrNWr6FCNOD3Tii/GhuGyISQ1X5nz6xHEc19EqAxdCTzzxhMzogQceEFcXXXTRqbXfz0znHypkdvl8tFevXl27ds33CUyMiyMp87cualZhjVm1hMjcDjnkELTrPHfxDJcJDwnObrvthpEpWGzW/ofDgW/5slEJjmRB/8iRfY455phTTjnlqKOOMiv1Otdz5kY/j1KGcePGuUtOnz4dbdksWZU55HJk5s1jbAnYymrrs0yPciIXedb4TQ2SX7dLFzoWtoR8oM6LomzO6pVkSFdgOflUSKXVYb3MvBJUamUsHuXi5jBAXuGp1oNWxEcJId5gvyM/9dRTcmMEkc8g8haSLOCXVHrkYTmpvE2ZVxXH0edMq1at+tWvfiXqhP3q1avlAhIBkeygGzBgwBe+8AXlR3Pi8XKzyicUgIDEjDmPHz/+ueeeMzfuHtfPhx1AzflselhMNuTM9zh27FiB59A+4IAD9ttvv5ztiZxax38okuPMmzfPBXDu3LkSLtR21llnDRo0yD3FNPSZaw7Z5NM/08lK7rzzTtml5QwdOnTYsGEylJg9F8CstDbIFkBGDztnMiozlnHlON7iVhyE3B977DG5jEVhUqTfvXt3PqMtVA15DkErNSGpTD5uQIYYXyslErQv0i67gHaNqLL1oLXwUeW1VckPBAbuOOKII/au/bdC6vNRhbcVVHoV76kYKvVBnAk40C233CIPck3LHwk57rjjnP8uI4MHDyYIvES7ktvFF9O2vsMtgupsJyMUdICPBIyg8ihlmzhx4qJFi6won6ZTkxwpLd/0sAPKwNczZszo2bMn4jjnnHPEhlQFO1c094eD/RO0bltur5Iv1GZcWaQJZJ6xZJILk5SJSBOklubAdOeff/6QIUPc0WwBzSibjLZpvkWQ3qB6NHNjKRFonz595EEOlUMPPdRa9t13X0tA02y1ZMkSSV8+WwwHgYa2mP8Q1KcSqiHYXxmnquAYsEGs5H6nw+ba1oGmsGwWt2mIT7vOfevPLo7+13/915xMioREJAXiUH11dkWtqX0N6aT5oQ5aCWZkJPvo0qXLZZddxpOEbrrShDdLQype2wQGCsjv2f8Hg8WmT9MI24oTbCh3mzZtGj5ytRQkTmNBZdrYCtG4RoG7yfz584WEu5sr0tFHH60TbYWKGYqi+uj6Q8BEOJERdKLEMrjGfAQ5SurWrRt6YhwTZknpm0xThFuCzC4/d6PT3FfNYtpWQe4U+QAU+X4wqJ5N0pKlRR6rxRrXQnKHMqi1EGzuqFGj7rnnHgsZPnz4YYcdlmSQsh7iciG1zFONeo/cST17ZtPVKy1ccnTttdei4G9/+9tOEZWtB62Fj+IQiQpL5m2JPVGBR9wUuLssBo8Iufhf/Ca+wpM0j5+B3ryCPL7yyis333zzrbfeKgm68sorhZbO6ccjq+jVSo0OU68MvKp11oRaf1sAFXWK25BgJZiPVMWlw6nuRilVYQePLkfeWqN5KtG0K9vAgQMZBCzH2+D9eHnzqOzAsCyGbmbPnu065r6jQxZTyRrSJQpYUvbRu/Z/xshejW7LYn/9ZCFa0RftH2w+7wkdhiPMISQeQaUJsENqqGUthjYfCrfffvsvf/lL2dMZZ5yBPb2Ns8XslfHfEzq3QCzsgJw8ebKcXar11a9+9eCDD96CPNsi0Fr46P3gOHqu9r+DiEzx4Lh2vjmQJeGuBrwN4klxL4K4racbScSdd9553XXXXXLJJaeccooDLT5UhV9DIXOOLIOzFoc8QSkevEUHpi3w3BRYIFe5TZBOhKVAinHq4009o8VWVVRDPE0TgjLCwoULxbmcCEUyqW413HnnnQ0N5qAmVNiY9gRrNEkGlHJyA/I//MM/yJUcct5appkjOPCq8qJqORY+d+5cbfnhCy+8wOBHHXWUmz4iTg+tCq2dj4DHLF261PVkzpw5PIPMt6QGQ4cOlTFR8CjYIJ9Mp4kIlLeL5LvuuktydNBBB9FHZCq5HZ2GjZ9NEM7lBokTQuYfWDK+kEChDEDZrCGoCK54Q4YM6dq1qyYV6Vi15h716RHd3HbbbSJ299o3mAQbrpH77LLLLm3bts3FhyUxjibaMiw1PWjiVdUtNKY9rd2ccQ355Zdfzi8/YvO/+Zu/keOYv7VYkbfVpZL1tLJ2NpQKYSIu9+qrr3bq1Gn//ffnQrJC9mETNqy3QGtAa+cjXsJd4k9izyUCK71U+4/PBM8JJ5yAZcRPjmhI8BDiKHfffffo0aN55De+8Q0pVRwuJq3ctAEh2nNcNz/X1h6qxbBmLkKmTp26fPnyNWvWeCVyBIxAosBc4QX1UsLPf/7zyRbVaFgZyhArVqxwh73nnnvchfWgJmxFv10NLrY9evQgHHDAAfkpW5pjwFBVICwb1pJgXRVroCRLli/znPPPPx9ZW3JYKQqyoaScaN0xNnbsWPbs16+fq1nnzp0ZQX7qrVbK+oatBK2dj6oQqgQMxatc3xzs8oJTTz312GOPFTOiKAddhSlTpvzoRz/iOl/84hfl2PGzhFzipwGdyfSwScVH6JXTC3iVQsWV4Zlnnnn++edRCVJgEAc11sDITnulaGEHbfHUNddcI9n55je/iYjTbUqjCDatMBH7DBgwYNCgQcjOoEm1tHVNVlJDeTo0Svfu3Q+pwUA0mVpvBjKHRuYj4RNjImuWtHyH2ahRo+69994LLrjgzDPPrP9AuuLZmTNnoq1nn31WKnTiiScyYBIi4IdJLWPJ1obWzkcCMhvP+5VhnJx4TzzxxMiRI13pRcgee+zheuKcF5AijfL02n9GRFMCxe0ElX4Y0yttOZZ+PDYaJVlvPauGhWU6y5YtQx9YOCzQs2dPOUubNm3cqtw+CBaeWLJkAWO9v/rVr0aMGCGcvva1r7GJfryyXoISp//zP//zokWLvvvd7+Z3dMMpbCIFw0qQz62kTpMmTTK0C2N+qiDnollxkG7zaFy2TWWDwLogs0JJufPi9Ouvv37x4sWynvPOOw+Pu+o659iZO61evXratGkY/4gjjnCS7f3Of3jFMpWVwKMO6/PE1oDWzkebXA0q5Lb/4osvPvbYY/Pnz1+4cOHKlSs5DdLhfJyGb4lVTCSBcvjzpDQMEwUq6x8bAfUUyd0txHKefvppx7VldurUaeDAgcgI/4qi6iMPyAKr5aAG+Ku/+ismuuqqq2RAFc2Fza+++mqENXz48Msvv1xlSN/oIRf9JPDQFr5DSW7K8oUHHngAQx1++OFugiZDAQytYRWoDYuEEvOGd+SP3MYqUDzmNX9L85ZJ0a5MEFsRUFj8pGpe66yVorXzUb0TkHPC1x/CPAkTuVZwMkHlWHOw0xGubvvybYlDzrd69tEVnZSpaRyYVRINS1NiBJEzderU448/HrdiIgrVyWxRllC/Cm+BNdxPH3roISnS7rvvfumll/bt2zcK2rrJ/vCHP3QH+bu/+7uuXbtmOMbZxBr6UWOIZBZKicPYsWMnT578rW9965hjjjGHeqs2LJxq5m8t4eJUzp0713KUHIYpdt11V5V71f5rSZc4pJ+E2gLVJC0NK9Wovvm/UQuPtx60dj4CDgFxo5zekavsoHIyxzj/4CUIiPfko0dtEzB8KCGnhqwJWX2jweTrHV1a9Ld/+7f9+/cfNmyYIBEYebXJze7dcAdBST/96U9Hjx592WWX5YNt9bKA73znO/PmzfvLv/xLnPLufkJDkQ3HvGkYzYkTJ/7bv/2ba+C55567c+1PGjG1twRl5MZBmBQfmbndtxxLA87jDmvOq1atCstQbteuHdtmCTWna/Y6rSJUZmm1aPST5yMAd4k3AKGSq6tKVZMfCbmdEUJGEDICfhZ/UhPaSn2jwTxNrzqH0AdGyC+4EUJG3gqwzZxVItCZT+ekk07q3r37mDFjZs+eHTYfOXLknDlzDjvssP33399jKutRbxnDVXbO0F26dGHwV199NbReERChMnXjIB8YyeMyN0sweVPlJx4J7msMK4UEatVy6r1OKzZpWIf5KFH4qOCDIDcpXLP33nufffbZrn6jRo3auHHjk08+ma8XS5dkN3TQzWZ4raCgHoWPCj4gnOfyF+f8CSecMHjwYPnR9773vR/84AdSp6FDh/bp08c1JHdDQnObgoLNovBRwQeBlAfcVqRIygsuuGDgwIGTJ09eu3btySefjJ68fbv2P+s3Nygo+ANQ+Kjgg6DKev6s9uclO3XqdN55533961//xje+ceqpp7Zp08ZNLV9K8jYfDBUU/F4UPir4gMjHsfKgJEF77bXXOeecc9JJJ+1W+8Nv1Qe3n37nF/oKCn4vCh8VfBDkC34ua7Kk6kdL/1P71kwU5EcbNmxQknFWKgsKNo/CRwUfBPlLQNhHcoSV0JPH7WogqEFSO+20kxJJhZUKCn4vCh+1OiSvSSIjc4mgkuwKhj5qWk2oT3YiBNVjLmVKlzINQz2AhiKATtKP/oPIXpkGWUkmvPXWW8rtt9/+7bff/u1vf6tSz/IvCh69SlmwDaPwUetCIr9CxRTr16/fuHFj5Kr+9dpfjMyjhnmVR3JQ1deTTk2rqQZwE1SPkCYq0R9BqQbyxcjFixfT2bH2n0p59DYgh/4KtmEUPmpdSPoj1OUdkdu1a9ejR48pU6ZMnDhx1apVifm82mGHHaQqZASBPpRpC+EUjzW2aYa2QR6buKfWBOq/gpS3aa5/AjU1HufNmzdhwgS3v7322itfpKx6gLBSwTaM8vtrrQuJcOyAUBCHCEc348ePv/HGG73t3r378ccff8ghh+S3YbyiU2vXhJBUaiLXo96RmnioxiOVUCFq9ZVmoly4cOGkSZMeeuihFStW9O/f/4orrkBJeYWq3NTySxW1FgXbLAoftUYk5bH1IReXtfnz5997771PPvkkCujUqVOfPn322Wefbt267bnnnp/+v//nolaQdOb3IsqEJESQhgTXQ/fBdevWTZ48GRnNnTt37dq1Xbp0GTRo0LnnnrvddtvJjzJPTRBo0q5arwXbLAoftS6gmyqqbX2+Qp0a1LBkyRLsgJVQAy7ARLvttlubNm06duzYuXNnPNWhQ4e2bdtiivwxzPdDE/HUQQ3qQUCGCCRBy5cvJ+Qv4e6+++5du3bt27fvwIED29f+l0rsk5/clTtaq0Lho9aFTSI8H9/gHQlIvkW9cuXKfLYtYUEZL774IirZsGHDm7X/8WmHHXZwlaMvf9EPyiCjJyU5PefHYW+99dYbb7yhJKt5rfbfrimNqJ8dd9wRr+lNQtS7d+9evXohOI+4rzav5m8MhJhSU9AaUPiodaHKj6Q/CfUwFDdQQ6iISfJCec2aNZgIj6AkPFVLbpr+byLwVlvQBDRXEwbRj04wlBKMiMXatWu36667KvFO+EhJlhDl25VITW/4K19uAh1mnnogqCn0tG2j8FHBHwSMI7WB5DvuWTwHX4DHCGrg47X/zgCwEhDUSHwIGEpilUyqfDhd8G4UPirYHLBMiEMZugGVsp4oBM0v3v96JbvRQ9WVHghKxFR7X1DQhMJHBR8EciJl+KVeyIc+hCpdCvJ7JJtAfdWwoAAKHxUUFDQKyhc6CgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaBYWPCgoKGgWFjwoKChoFhY8KCgoaAx/72P8Db0YqCEUWhYcAAAAASUVORK5CYII=" /></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients, listed in section 6.1. Concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAO-inhibitors) is contraindicated due to the risk of serotonin syndrome with agitation, tremor, hyperthermia etc. (see section 4.5).

The combination of escitalopram with reversible MAO-A inhibitors (e.g. moclobemide) or the reversible non-selective MAO-inhibitor linezolid is contraindicated due to the risk of onset of a serotonin syndrome (see section 4.5).

Escitalopram is contraindicated in patients with known QT interval prolongation or congenital long QT syndrome.

Escitalopram is contraindicated together with medicinal products that are known to prolong the QT interval (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following special warnings and precautions apply to the therapeutic class of SSRIs (Selective Serotonin Re-uptake Inhibitors).</p><p><u>Paediatric population</u><br />Inment should not be used in the treatment of paediatric population. Suicide related behaviours (suicide attempt and suicidal thoughts), and hostility (predominately aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among the paediatric population treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in the paediatric population concerning growth, maturation and cognitive and behavioural development are lacking.</p><p><u>Paradoxical anxiety</u><br />Some patients with panic disorder may experience increased anxiety symptoms at the beginning of treatment with antidepressants. This paradoxical reaction usually subsides within two weeks&nbsp;during continued treatment. A low starting dose is advised to reduce the likelihood of an anxiogenic effect (see section 4.2).</p><p><u>Seizures</u><br />Escitalopram should be discontinued if a patient develops seizures for the first time, or if there is an increase in seizure frequency (in patients with a previous diagnosis of epilepsy). SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored.</p><p><u>Mania</u><br />SSRIs should be used with caution in patients with a history of mania/hypomania. SSRIs should be discontinued in any patient entering a manic phase.</p><p><u>Diabetes</u><br />In patients with diabetes, treatment with an SSRI may alter glycaemic control (hypoglycaemia or hyperglycaemia). Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p><u>Suicide/suicidal thoughts or clinical worsening</u><br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which Inment is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta analysis of placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes.</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p><u>Akathisia/psychomotor restlessness</u><br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><u>Hyponatraemia</u><br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported rarely with the use of SSRIs and generally resolves on discontinuation of therapy. Caution should be exercised in patients at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.</p><p><u>Haemorrhage</u><br />There have been reports of cutaneous bleeding abnormalities, such as ecchymoses and purpura, with SSRIs. SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections 4.6, 4.8). Caution is advised in patients taking SSRIs, particularly in concomitant use with oral anticoagulants, with medicinal products known to affect platelet function (e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory medicinal products (NSAIDs), ticlopidine and dipyridamole) and in patients with known bleeding tendencies.</p><p><u>ECT (electroconvulsive therapy)</u><br />There is limited clinical experience of concurrent administration of SSRIs and ECT, therefore caution is advisable.</p><p><u>Serotonin syndrome</u><br />Caution is advisable if escitalopram is used concomitantly with medicinal products with serotonergic effects such as triptans (including sumatriptan), opioids (including tramadol), and tryptophan.</p><p>In rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic medicinal products. A combination of symptoms, such as agitation, tremor, myoclonus and hyperthermia may indicate the development of this condition. If this occurs treatment with the SSRI and the serotonergic medicinal product should be discontinued immediately and symptomatic treatment initiated.</p><p><u>St. John&#39;s wort</u><br />Concomitant use of SSRIs and herbal remedies containing St. John&#39;s wort (Hypericum perforatum) may result in an increased incidence of adverse reactions (see section 4.5).</p><p><u>Discontinuation symptoms seen when stopping treatment</u><br />Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials adverse events seen on treatment discontinuation occurred in approximately 25% of patients treated with escitalopram and 15% of patients taking placebo.</p><p>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.</p><p>They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.</p><p>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see &ldquo;Discontinuation symptoms seen when stopping treatment&rdquo;, section 4.2).</p><p><u>Sexual dysfunction</u><br />Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.</p><p><u>St. John&#39;s wort</u><br />Concomitant use of SSRIs and herbal remedies containing St. John&#39;s wort (Hypericum perforatum) may result in an increased incidence of adverse reactions (see section 4.5).<br />Discontinuation symptoms seen when stopping treatment<br />Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials adverse events seen on treatment discontinuation occurred in approximately 25% of patients treated with escitalopram and 15% of patients taking placebo.<br />The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.<br />They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.<br />Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see &ldquo;Discontinuation symptoms seen when stopping treatment&rdquo;, section 4.2).</p><p><u>Sexual dysfunction</u><br />Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.</p><p><u>Coronary heart disease</u><br />Due to limited clinical experience, caution is advised in patients with coronary heart disease (see section 5.3).</p><p><u>QT interval prolongation</u><br />Escitalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been&nbsp;reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases (see sections 4.3, 4.5, 4.8, 4.9 and 5.1).</p><p>Caution is advised in patients with significant bradycardia; or in patients with recent acute myocardial infarction or uncompensated heart failure.<br />Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for malignant arrhythmias and should be corrected before treatment with escitalopram is started.<br />If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started.</p><p>If signs of cardiac arrhythmia occur during treatment with escitalopram, the treatment should be withdrawn and an ECG should be performed.</p><p><u>Angle-Closure Glaucoma</u><br />SSRIs including escitalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Escitalopram should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindicated combinations:</u><br /><em>Irreversible non-selective MAOIs</em><br />Cases of serious reactions have been reported in patients receiving an SSRI in combination with a non-selective, irreversible monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued SSRI treatment and have been started on such MAOI treatment (see section 4.3). In some cases, the patient developed serotonin syndrome (see section 4.8).</p><p><br />Escitalopram is contraindicated in combination with non-selective, irreversible MAOIs. Escitalopram may be started 14 days after discontinuing treatment with an irreversible MAOI. At least 7 days should elapse after discontinuing escitalopram treatment, before starting a non-selective, irreversible MAOI.</p><p><br /><em>Reversible, selective MAO-A inhibitor (moclobemide)</em><br />Due to the risk of serotonin syndrome, the combination of escitalopram with a MAO-A inhibitor such as moclobemide is contraindicated (see section 4.3). If the combination proves necessary, it should be started at the minimum recommended dosage and clinical monitoring should be reinforced.</p><p><em>Reversible, non-selective MAO-inhibitor (linezolid)</em><br />The antibiotic linezolid is a reversible non-selective MAO-inhibitor and should not be given to patients treated with escitalopram. If the combination proves necessary, it should be given with minimum dosages and under close clinical monitoring (see section 4.3).</p><p><br /><em>Irreversible, selective MAO-B inhibitor (selegiline)</em><br />In combination with selegiline (irreversible MAO-B inhibitor), caution is required due to the risk of developing serotonin syndrome. Selegiline doses up to 10 mg/day have been safely co-administered with racemic citalopram.</p><p><br /><em>QT interval prolongation</em><br />Pharmacokinetic and pharmacodynamic studies of escitalopram combined with other medicinal products that prolong the QT interval have not been performed. An additive effect of escitalopram and these medicinal products cannot be excluded. Therefore, co-administration of escitalopram with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (e.g. astemizole, hydroxyzine, mizolastine), is contraindicated.</p><p><br /><u>Combinations requiring precautions for use:</u><br /><em>Serotonergic medicinal products</em><br />Co-administration with serotonergic medicinal products (e.g. opioids (including tramadol), and triptans (including sumatriptan) may lead to serotonin syndrome (see section 4.4).</p><p><br /><em>Medicinal products lowering the seizure threshold</em><br />SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g antidepressants (tricyclics, SSRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquin, bupropion and tramadol).</p><p><em>Lithium, tryptophan</em><br />There have been reports of enhanced effects when SSRIs have been given together with lithium or tryptophan, therefore concomitant use of SSRIs with these medicinal products should be undertaken with caution.</p><p><br /><em>St. John&#39;s wort</em><br />Concomitant use of SSRIs and herbal remedies containing St. John&acute;s wort (Hypericum perforatum) may result in an increased incidence of adverse reactions (see section4.4)</p><p><em>Haemorrhage</em><br />Altered anti-coagulant effects may occur when escitalopram is combined with oral anticoagulants. Patients receiving oral anticoagulant therapy should receive careful coagulation monitoring when escitalopram is started or stopped (see section 4.4). Concomitant use of non-steriodal anti-inflammatory drugs (NSAIDs) may increase bleeding-tendency (see section 4.4).</p><p>&nbsp;</p><p><em>Alcohol</em><br />No pharmacodynamic or pharmacokinetic interactions are expected between escitalopram and alcohol. However, as with other psychotropic medicinal products, the combination with alcohol is not advisable.</p><p>&nbsp;</p><p><em>Medicinal products inducing hypokalaemia/hypomagnesaemia</em><br />Caution is warranted for concomitant use of hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias (see section 4.4).</p><p>&nbsp;</p><p><strong>Pharmacokinetic interactions</strong><br /><u>Influence of other medicinal products on the pharmacokinetics of escitalopram</u><br />The metabolism of escitalopram is mainly mediated by CYP2C19. CYP3A4 and CYP2D6 may also contribute to the metabolism although to a smaller extent. The metabolism of the major metabolite S-DCT (demethylated escitalopram) seems to be partly catalysed by CYP2D6.</p><p>Co-administration of escitalopram with omeprazole 30 mg once daily (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram.</p><p>Co-administration of escitalopram with cimetidine 400 mg twice daily (moderately potent general enzyme-inhibitor) resulted in a moderate (approximately 70%) increase in the plasma concentrations of escitalopram. Caution is advised when administering escitalopram in combination with cimetidine. Dose adjustment may be warranted.</p><p>Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluconazole, fluvoxamine, lansoprazole, ticlopidine) or cimetidine. A reduction in the dose of escitalopram may be necessary based on monitoring of side-effects during concomitant treatment (see section 4.4).</p><p><br /><u>Effect of escitalopram on the pharmacokinetics of other medicinal products</u><br />Escitalopram is an inhibitor of the enzyme CYP2D6. Caution is recommended when escitalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted.</p><p>Co-administration with desipramine or metoprolol resulted in both cases in a twofold increase in the plasma levels of these two CYP2D6 substrates.<br />In vitro studies have demonstrated that escitalopram may also cause weak inhibition of CYP2C19. Caution is recommended with concomitant use of medicinal products that are metabolised by CYP2C19.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />For escitalopram only limited clinical data are available regarding exposed pregnancies.</p><p>Animal studies have shown reproductive toxicity (see section 5.3). Inment should not be used during pregnancy unless clearly necessary and only after careful consideration of the risk/benefit.</p><p>Neonates should be observed if maternal use of Inment continues into the later stages of pregnancy, particularly in the third trimester. Abrupt discontinuation should be avoided during pregnancy.</p><p>The following symptoms may occur in the neonate after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours) after delivery.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p><u>Breast-feeding</u><br />It is expected that escitalopram will be excreted into human milk.</p><p><br />Consequently, breast-feeding is not recommended during treatment.</p><p><u>Fertility</u></p><p>Animal data have shown that citalopram may affect sperm quality (see section 5.3). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although escitalopram has been shown not to affect intellectual function or psychomotor performance, any psychoactive medicinal product may impair judgement or skills. Patients should be cautioned about the potential risk of an influence on their ability to drive a car and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions known for SSRIs and also reported for escitalopram in either placebo-controlled clinical studies or as spontaneous post-marketing events are listed below by system organ class and frequency.</p><p>Frequencies are taken from clinical studies; they are not placebo-corrected. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Inappropriate ADH secretion</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite, increased appetite, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hyponatraemia, anorexia<sup>1</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety, restlessness, abnormal dreams</p><p>libido decreased</p><p>Female: anorgasmia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Bruxism, agitation, nervousness, panic attack, confusional state</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Aggression, depersonalisation, hallucination</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Mania, suicidal ideation, suicidal behaviour<sup>2</sup></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia, somnolence, dizziness, paraesthesia, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Taste disturbance, sleep disorder, syncope</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Serotonin syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Dyskinesia, movement disorder, convulsion, psychomotor restlessness/akathisia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Mydriasis, visual disturbance</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged Ventricular arrhythmia including torsade de pointes</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sinusitis, yawning</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Epistaxis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea, constipation, vomiting, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhages (including rectal haemorrhage)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatitis, liver function test abnormal</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sweating increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria, alopecia, rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Ecchymosis, angioedemas</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Urinary retention</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Male: ejaculation disorder, impotence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Female: metrorrhagia, menorrhagia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Galactorrhoea</p><p>Male: priapism</p><p>Postpartum haemorrhage<sup>3</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr></tbody></table><p>1 These events have been reported for the therapeutic class of SSRIs.</p><p>2 Cases of suicidal ideation and suicidal behaviours have been reported during escitalopram therapy or early after treatment discontinuation (see section 4.4).</p><p>3 This event has been reported for the therapeutic class of SSRIs/SNRIs (see section 4.4 and 4.6).</p><p><u>QT interval prolongation</u></p><p>&nbsp;Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases (see sections 4.3, 4.4, 4.5, 4.9 and 5.1).</p><p><u>Class effects</u></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p><u>Discontinuation symptoms seen when stopping treatment</u></p><p>Discontinuation of SSRIs/SNRIs (particularly when abrupt) commonly leads to discontinuation symptoms. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when escitalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and 4.4).</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:<br />&bull; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><br />&bull; Other GCC States<br />Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>Clinical data on escitalopram overdose are limited and many cases involve concomitant overdoses of other drugs. In the majority of cases mild or no symptoms have been reported. Fatal cases of escitalopram overdose have rarely been reported with escitalopram alone; the majority of cases have involved overdose with concomitant medications. Doses between 400 and 800 mg of escitalopram alone have been taken without any severe symptoms.</p><p><u>Symptoms</u></p><p>Symptoms seen in reported overdose of escitalopram include symptoms mainly related to the central nervous system (ranging from dizziness, tremor, and agitation to rare cases of serotonin syndrome, convulsion, and coma), the gastrointestinal system (nausea/vomiting), and the cardiovascular system (hypotension, tachycardia, QT interval prolongation, and arrhythmia) and electrolyte/fluid balance conditions (hypokalaemia, hyponatraemia).</p><p><u>Management</u></p><p>There is no specific antidote. Establish and maintain an airway, ensure adequate oxygenation and respiratory function. Gastric lavage and the use of activated charcoal should be considered. Gastric lavage should be carried out as soon as possible after oral ingestion. Cardiac and vital signs monitoring are recommended along with general symptomatic supportive measures.</p><p>ECG monitoring is advised in case of overdose in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antidepressants, selective serotonin reuptake inhibitors.</p><p>ATC-code: N 06 AB 10</p><p><u>Mechanism of action </u></p><p>Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with high affinity for the primary binding site. It also binds to an allosteric site on the serotonin transporter, with a 1000 fold lower affinity.</p><p>Escitalopram has no or low affinity for a number of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, &alpha;1-, &alpha;2-, &beta;-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine, and opioid receptors.</p><p>The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of escitalopram.</p><p><u>Pharmacodynamic effects</u></p><p>In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 4.3 ms (90% CI: 2.2, 6.4) at the 10 mg/day dose and 10.7 ms (90% CI: 8.6, 12.8) at the supratherapeutic dose 30 mg/day (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p><p><u>Clinical efficacy</u></p><p><em>Major depressive episodes</em></p><p>Escitalopram has been found to be effective in the acute treatment of major depressive episodes in three out of four double-blind, placebo controlled short-term (8-week) studies. In a long-term relapse prevention study, 274 patients who had responded during an initial 8-week open label treatment phase with escitalopram 10 or 20 mg/day, were randomised to continuation with escitalopram at the same dose, or to placebo, for up to 36 weeks. In this study, patients receiving continued escitalopram experienced a significantly longer time to relapse over the subsequent 36 weeks compared to those receiving placebo.</p><p><em>Social anxiety disorder </em></p><p>Escitalopram was effective in both three short-term (12- week) studies and in responders in a 6-month relapse prevention study in social anxiety disorder. In a 24-week dose-finding study, efficacy of 5, 10 and 20 mg escitalopram has been demonstrated.</p><p><em>Generalised anxiety disorder </em></p><p>Escitalopram in doses of 10 and 20 mg/day was effective in four out of four placebo-controlled studies.</p><p>In pooled data from three studies with similar design comprising 421 escitalopram-treated patients and 419 placebo-treated patients there were 47.5% and 28.9% responders respectively and 37.1% and 20.8% remitters. Sustained effect was seen from week 1.</p><p>Maintenance of efficacy of escitalopram 20mg/day was demonstrated in a 24 to 76 week, randomised, maintenance of efficacy study in 373 patients who had responded during the initial 12-week open-label treatment.</p><p><em>Obsessive-compulsive disorder</em></p><p>In a randomised, double-blind, clinical study, 20 mg/day escitalopram separated from placebo on the Y-BOCS total score after 12 weeks. After 24 weeks, both 10 and 20 mg/day escitalopram were superior as compared to&nbsp;placebo.</p><p>Prevention of relapse was demonstrated for 10 and 20 mg/day escitalopram in patients who responded to escitalopram in a 16-week open-label period and who entered a 24-week, randomised, double-blind, placebo controlled period.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Absorption is almost complete and independent of food intake. (Mean time to maximum concentration (mean Tmax) is 4 hours after multiple dosing).</p><p>As with racemic citalopram, the absolute bioavailability of escitalopram is expected to be about 80%.</p><p><u>Distribution </u></p><p>The apparent volume of distribution (Vd,&beta;/F) after oral administration is about 12 to 26 L/kg. The plasma protein binding is below 80% for escitalopram and its main metabolites.</p><p><u>Biotransformation</u></p><p>Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N-oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28-31% and &lt;5%, respectively, of the escitalopram concentration. Biotransformation of escitalopram to the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible.</p><p><u>Elimination</u></p><p>The elimination half-life (t&frac12; &beta;) after multiple dosing is about 30 hours and the oral plasma clearance (Cloral) is about 0.6 L/min. The major metabolites have a significantly longer half-life. Escitalopram and major metabolites are assumed to be eliminated by both the hepatic (metabolic) and the renal routes, with the major part of the dose excreted as metabolites in the urine.</p><p><u>Linearity </u></p><p>There is linear pharmacokinetics. Steady-state plasma levels are achieved in about 1 week. Average steady-state concentrations of 50 nmol/L (range 20 to 125 nmol/L) are achieved at a daily dose of 10 mg.</p><p><u>Elderly patients (&gt; 65 years)</u></p><p>Escitalopram appears to be eliminated more slowly in elderly patients compared to younger patients. Systemic exposure (AUC) is about 50 % higher in elderly compared to young healthy volunteers (see section 4.2).</p><p><u>Reduced hepatic function</u></p><p>In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of escitalopram was about twice as long and the exposure was about 60% higher than in subjects with normal liver function (see section 4.2).</p><p><u>Reduced renal function</u></p><p>With racemic citalopram, a longer half-life and a minor increase in exposure have been observed in patients with reduced kidney function (CLcr 10-53 ml/min). Plasma concentrations of the metabolites have not been studied, but they may be elevated (see section 4.2).</p><p><u>Polymorphism</u></p><p>It has been observed that poor metabolisers with respect to CYP2C19 have twice as high a plasma concentration of escitalopram as extensive metabolisers. No significant change in exposure was observed in poor metabolisers with respect to CYP2D6 (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No complete conventional battery of preclinical studies was performed with escitalopram since the bridging toxicokinetic and toxicological studies conducted in rats with escitalopram and citalopram showed a similar profile. Therefore, all the citalopram information can be extrapolated to escitalopram.</p><p>&nbsp;</p><p>In comparative toxicological studies in rats, escitalopram and citalopram caused cardiac toxicity, including congestive heart failure, after treatment for some weeks, when using dosages that caused general toxicity. The cardiotoxicity seemed to correlate with peak plasma concentrations rather than to systemic exposures (AUC). Peak plasma concentrations at no-effect-level were in excess (8-fold) of those achieved in clinical use, while AUC for escitalopram was only 3- to 4-fold higher than the exposure achieved in clinical use. For citalopram AUC values for the S-enantiomer were 6- to 7-fold higher than exposure achieved in clinical use. The findings are probably related to an exaggerated influence on biogenic amines i.e. secondary to the primary pharmacological effects, resulting in haemodynamic effects (reduction in coronary flow) and ischaemia. However, the exact mechanism of cardiotoxicity in rats is not clear. Clinical experience with citalopram, and the clinical trial experience with escitalopram, do not indicate that these findings have a clinical correlate.</p><p>&nbsp;</p><p>Increased content of phospholipids has been observed in some tissues e.g. lung, epididymides and liver after treatment for longer periods with escitalopram and citalopram in rats. Findings in the epididymides and liver were seen at exposures similar to that in man. The effect&nbsp;is reversible&nbsp;after treatment cessation. Accumulation of phospholipids (phospholipidosis) in animals has been observed in connection with many cationic amphiphilic medicines. It is not known if this phenomenon has any significant relevance for man.</p><p>&nbsp;</p><p>In the developmental toxicity study in the rat embryotoxic effects (reduced foetal weight and reversible delay of ossification) were observed at exposures in terms of AUC in excess of the exposure achieved during clinical use. No increased frequency of malformations was noted. A pre- and postnatal study showed reduced survival during the lactation period at exposures in terms of AUC in excess of the exposure achieved during clinical use.</p><p>Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in implantation number and abnormal sperm at exposure well in excess of human exposure. No animal data related to this aspect are available for escitalopram.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />&minus; Microcrystalline cellulose<br />&minus; Croscarmellose sodium<br />&minus; Colloidal silicon dioxide<br />&minus; Purified talc<br />&minus; Magnesium stearate.</p><p>&nbsp;</p><p>Tablet coat:<br />&minus; Hypromellose<br />&minus; Titanium dioxide<br />&minus; Polyethylene glycol/macrogol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p><br />Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inment 10 mg and 20 mg Film-coated Tablets are supplied in blisters.<br />The materials of the blister consist of polyvinyl chloride, polyethylene and coated with a polyvinylidene chloride (PVDC) layer with an aluminium foil lidding coated with a thermosealable lacquer.</p><p>&nbsp;</p><p>Pack size:<br />Inment 10 mg and 20 mg: 28 Film-coated Tablets (2 blisters of 14&rsquo;s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrazi Pharmaceutical Industries Factory Co.,
2nd Industrial City, Street no. 67, Cross 110, Building no. 3992,
Dammam, Kingdom of Saudi Arabia
Tel.: +966 13 8281919,
Fax: +966 13 8281313,
E-mail: info@alrazi-pharma.com
Website: www.alrazi-pharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02 November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>